Transactivation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
identification	O
of	O
transactivating	B-DNA
HHV-6	I-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
gene	I-DNA
fragments	I-DNA
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
promoter	I-DNA
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O

Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	B-DNA
in	O
both	O
stimulated	O
and	O
resting	O
T	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	B-DNA
promoter	I-DNA
activity	O
only	O
in	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
genomic	I-DNA
fragments	I-DNA
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
cotransfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
21.4-kb	B-DNA
DNA	I-DNA
clone	I-DNA
,	O
pZVB70	B-DNA
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	B-DNA
fragments	I-DNA
,	O
pZVB10	B-DNA
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	B-DNA
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	B-DNA
,	O
activated	O
the	O
HIV	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
a	O
mutation	O
in	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

However	O
,	O
this	O
mutated	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
promoter	I-DNA
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	B-DNA
or	O
pZVB10	B-DNA
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
of	O
the	O
HIV	B-DNA
promoter	I-DNA
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	B-DNA
promoter	I-DNA
activity	O
in	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
June	NULL
1991	NULL
,	NULL
p.	NULL
2895-2902	NULL
0022-538	NULL
X/91/062895-08	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1991	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

65	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Transactivation	NULL
of	NULL
the	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Promoter	NULL
by	NULL
Human	NULL
Herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
Strains	NULL
GS	NULL
and	NULL
Z-29	NULL
in	NULL
Primary	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
and	NULL
Identification	NULL
of	NULL
Transactivating	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
Gene	NULL
Fragments	NULL
REBECCA	NULL
T.	NULL
HORVAT	NULL
,	NULL
't	NULL
CHARLES	NULL
WOOD	NULL
,	NULL
*	NULL
STEVEN	NULL
F.	NULL
JOSEPHS	NULL
,	NULL
``	NULL
anp	NULL
N.	NULL
BALACHANDRAN®	NULL
}	NULL
*	NULL
Department	NULL
of	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Kansas	NULL
,	NULL
Lawrence	NULL
,	NULL
Kansas	NULL
66045	NULL
)	NULL
;	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
``	NULL
;	NULL
and	NULL
Department	NULL
of	NULL
Microbiology	NULL
,	NULL
Molecular	NULL
Genetics	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Kansas	NULL
Medical	NULL
Center	NULL
,	NULL
Kansas	NULL
City	NULL
,	NULL
Kansas	NULL
66103°	NULL
Received	NULL
27	NULL
December	NULL
1990/Accepted	NULL
2	NULL
March	NULL
1991	NULL
Human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
can	NULL
activate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
promoter	NULL
and	NULL
accelerate	NULL
cytopathic	NULL
effects	NULL
in	NULL
HIV-infected	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
study	NULL
examines	NULL
the	NULL
regions	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
required	NULL
for	NULL
HHV-6	NULL
transactivation	NULL
in	NULL
a	NULL
heterogeneous	NULL
population	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
with	NULL
or	NULL
without	NULL
antigenic	NULL
stimulation	NULL
.	NULL

Two	NULL
different	NULL
strains	NULL
of	NULL
HHV-6	NULL
,	NULL
GS	NULL
and	NULL
229	NULL
,	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

The	NULL
GS	NULL
strain	NULL
transactivated	NULL
the	NULL
promoter	NULL
in	NULL
both	NULL
stimulated	NULL
and	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
Z29	NULL
strain	NULL
increased	NULL
HIV	NULL
promoter	NULL
activity	NULL
only	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
.	NULL

Three	NULL
DNA	NULL
clones	NULL
containing	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
genomic	NULL
fragments	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
cotransfected	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
21.4-kb	NULL
DNA	NULL
clone	NULL
,	NULL
pZVB70	NULL
,	NULL
showed	NULL
the	NULL
highest	NULL
transactivating	NULL
ability	NULL
,	NULL
while	NULL
two	NULL
other	NULL
DNA	NULL
fragments	NULL
,	NULL
pZVB10	NULL
(	NULL
6.2	NULL
kb	NULL
)	NULL
and	NULL
pZVH14	NULL
(	NULL
8.7	NULL
kb	NULL
)	NULL
,	NULL
showed	NULL
lower	NULL
activity	NULL
.	NULL

One	NULL
of	NULL
these	NULL
clones	NULL
,	NULL
pZVH14	NULL
,	NULL
activated	NULL
the	NULL
HIV	NULL
promoter	NULL
construct	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
NFB	NULL
site	NULL
.	NULL

However	NULL
,	NULL
this	NULL
mutated	NULL
NFB	NULL
promoter	NULL
was	NULL
not	NULL
transactivated	NULL
during	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
or	NULL
after	NULL
cotransfection	NULL
with	NULL
pZVB70	NULL
or	NULL
pZVB10	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
NFB	NULL
sites	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
are	NULL
essential	NULL
for	NULL
its	NULL
transactivation	NULL
during	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
.	NULL

By	NULL
increasing	NULL
HIV	NULL
promoter	NULL
activity	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
,	NULL
HHV-6	NULL
may	NULL
consequently	NULL
increase	NULL
HIV	NULL
replication	NULL
,	NULL
leading	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
cytopathic	NULL
effect	NULL
on	NULL
coinfected	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Human	NULL
CD4+	NULL
T	NULL
lymphocytes	NULL
are	NULL
the	NULL
primary	NULL
target	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
(	NULL
4	NULL
,	NULL
20	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Infection	NULL
with	NULL
HIV	NULL
results	NULL
in	NULL
the	NULL
eventual	NULL
development	NULL
of	NULL
AIDS	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
23	NULL
)	NULL
.	NULL

HIV	NULL
replication	NULL
can	NULL
be	NULL
shown	NULL
in	NULL
only	NULL
a	NULL
small	NULL
percentage	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
seems	NULL
to	NULL
persist	NULL
for	NULL
long	NULL
periods	NULL
of	NULL
time	NULL
in	NULL
a	NULL
latent	NULL
phase	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
virus	NULL
exists	NULL
in	NULL
a	NULL
latent	NULL
phase	NULL
,	NULL
infected	NULL
individuals	NULL
may	NULL
not	NULL
develop	NULL
clinical	NULL
manifestations	NULL
of	NULL
AIDS	NULL
for	NULL
years	NULL
after	NULL
the	NULL
initial	NULL
HIV	NULL
infection	NULL
(	NULL
2	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
latent	NULL
HIV	NULL
virus	NULL
can	NULL
be	NULL
reactivated	NULL
by	NULL
various	NULL
agents	NULL
such	NULL
as	NULL
antigen	NULL
,	NULL
mitogen	NULL
,	NULL
or	NULL
cytokine	NULL
stimulation	NULL
(	NULL
7	NULL
,	NULL
21	NULL
)	NULL
.	NULL

A	NULL
wide	NULL
range	NULL
of	NULL
antigenic	NULL
stimulation	NULL
and	NULL
viral	NULL
infections	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
various	NULL
cell	NULL
lines	NULL
(	NULL
13	NULL
,	NULL
22	NULL
,	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
to	NULL
what	NULL
extent	NULL
these	NULL
events	NULL
occur	NULL
in	NULL
vivo	NULL
,	NULL
and	NULL
the	NULL
mechanisms	NULL
involved	NULL
are	NULL
not	NULL
yet	NULL
completely	NULL
understood	NULL
.	NULL

A	NULL
new	NULL
lymphotropic	NULL
herpesvirus	NULL
,	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
of	NULL
patients	NULL
with	NULL
AIDS	NULL
(	NULL
35	NULL
,	NULL
39	NULL
)	NULL
,	NULL
from	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
(	NULL
35	NULL
)	NULL
,	NULL
and	NULL
from	NULL
infants	NULL
with	NULL
exanthem	NULL
subitum	NULL
(	NULL
34	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Immunological	NULL
and	NULL
molecular	NULL
analyses	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
new	NULL
herpesvirus	NULL
is	NULL
distinct	NULL
from	NULL
other	NULL
human	NULL
herpesviruses	NULL
(	NULL
17	NULL
,	NULL
18	NULL
,	NULL
25	NULL
)	NULL
.	NULL

HHV-6	NULL
productively	NULL
infects	NULL
CD4+	NULL
human	NULL
T	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
the	NULL
HHV-6	NULL
strains	NULL
show	NULL
variations	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
infect	NULL
various	NULL
T	NULL
cells	NULL
and	NULL
T-cell	NULL
lines	NULL
(	NULL
41	NULL
)	NULL
.	NULL

They	NULL
also	NULL
differ	NULL
in	NULL
antigenic	NULL
properties	NULL
(	NULL
41	NULL
)	NULL
and	NULL
exhibit	NULL
DNA	NULL
restriction	NULL
site	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

t	NULL
Present	NULL
address	NULL
:	NULL
Clinical	NULL
Laboratories	NULL
,	NULL
University	NULL
of	NULL
Kansas	NULL
Medical	NULL
Center	NULL
,	NULL
Kansas	NULL
City	NULL
,	NULL
KS	NULL
66103	NULL
.	NULL

+	NULL
Present	NULL
address	NULL
:	NULL
Universal	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20850	NULL
.	NULL

2895	NULL
heterogeneity	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
prototype	NULL
strain	NULL
,	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
,	NULL
infected	NULL
a	NULL
number	NULL
of	NULL
T-cell	NULL
lines	NULL
as	NULL
well	NULL
as	NULL
human	NULL
B	NULL
lymphocytes	NULL
,	NULL
glioblastoma	NULL
cells	NULL
,	NULL
and	NULL
megakaryocytic	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
,	NULL
isolated	NULL
from	NULL
a	NULL
Zairian	NULL
AIDS	NULL
patient	NULL
,	NULL
infected	NULL
phytohemagglutinin-stimulated	NULL
lymphocytes	NULL
from	NULL
cord	NULL
blood	NULL
or	NULL
from	NULL
adult	NULL
peripheral	NULL
blood	NULL
but	NULL
failed	NULL
to	NULL
replicate	NULL
in	NULL
unstimulated	NULL
lymphocytes	NULL
and	NULL
certain	NULL
T-cell	NULL
lines	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
have	NULL
grown	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
in	NULL
the	NULL
Molt-3	NULL
T-cell	NULL
line	NULL
,	NULL
in	NULL
which	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
failed	NULL
to	NULL
replicate	NULL
.	NULL

HHV-6	NULL
infects	NULL
many	NULL
of	NULL
the	NULL
same	NULL
target	NULL
cells	NULL
as	NULL
HIV	NULL
(	NULL
26	NULL
)	NULL
,	NULL
and	NULL
in	NULL
vitro	NULL
,	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
can	NULL
also	NULL
productively	NULL
coinfect	NULL
HIV-infected	NULL
CD4+	NULL
T	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
24	NULL
,	NULL
26	NULL
)	NULL
.	NULL

One	NULL
study	NULL
showed	NULL
that	NULL
this	NULL
leads	NULL
to	NULL
accelerated	NULL
cytopathic	NULL
effects	NULL
in	NULL
comparison	NULL
with	NULL
HIV	NULL
or	NULL
HHV-6	NULL
infection	NULL
alone	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
our	NULL
previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
is	NULL
activated	NULL
in	NULL
HHV-6-infected	NULL
T-cell	NULL
lines	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
leads	NULL
to	NULL
increased	NULL
HIV	NULL
gene	NULL
expression	NULL
,	NULL
which	NULL
ultimately	NULL
leads	NULL
to	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
virus	NULL
replication	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
HHV-6	NULL
can	NULL
act	NULL
as	NULL
a	NULL
cofactor	NULL
in	NULL
the	NULL
development	NULL
and	NULL
possibly	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
AIDS	NULL
.	NULL

To	NULL
study	NULL
the	NULL
activation	NULL
of	NULL
HIV	NULL
by	NULL
HHV-6	NULL
under	NULL
more	NULL
physiologic	NULL
conditions	NULL
,	NULL
we	NULL
have	NULL
assessed	NULL
whether	NULL
or	NULL
not	NULL
HHV-6	NULL
infection	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
can	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
specific	NULL
antigenic	NULL
stimulation	NULL
in	NULL
combination	NULL
with	NULL
infection	NULL
by	NULL
two	NULL
strains	NULL
of	NULL
HHV-6	NULL
were	NULL
examined	NULL
.	NULL

Results	NULL
of	NULL
the	NULL
study	NULL
indicate	NULL
that	NULL
HHV-6	NULL
strains	NULL
GS	NULL
and	NULL
Z29	NULL
can	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
differed	NULL
in	NULL
their	NULL
dependency	NULL
on	NULL
antigenic	NULL
stimulation	NULL
for	NULL
transactivation	NULL
.	NULL

Transactivation	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
involves	NULL
the	NULL
NFkB	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
.	NULL

We	NULL
have	NULL
also	NULL
identified	NULL
three	NULL
2896	NULL
HORVAT	NULL
ET	NULL
AL	NULL
.	NULL

different	NULL
cloned	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
fragments	NULL
that	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
after	NULL
cotransfection	NULL
into	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
DNA	NULL
and	NULL
plasmids	NULL
.	NULL

The	NULL
HIV	NULL
chloramphenical	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
plasmid	NULL
has	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
construct	NULL
contains	NULL
both	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
and	NULL
the	NULL
repeat	NULL
sequences	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
aligned	NULL
with	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

The	NULL
-147	NULL
CAT	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
deleting	NULL
a	NULL
fragment	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
at	NULL
the	NULL
Aval	NULL
site	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
-57	NULL
CAT	NULL
plasmid	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Joseph	NULL
Sodroski	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
HIV	NULL
LTR	NULL
plasmid	NULL
containing	NULL
the	NULL
mutated	NULL
NFB	NULL
site	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Gary	NULL
Nabel	NULL
(	NULL
27	NULL
)	NULL
.	NULL

BamHI	NULL
plasmid	NULL
libraries	NULL
of	NULL
the	NULL
HHV-6	NULL
genome	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

HHV-6	NULL
viral	NULL
strains	NULL
and	NULL
preparation	NULL
.	NULL

The	NULL
human	NULL
T-cell	NULL
lines	NULL
HSB-2	NULL
(	NULL
ATCC	NULL
CCL120.1	NULL
CCRF-HSB-2	NULL
)	NULL
and	NULL
Molt-3	NULL
(	NULL
ATCC	NULL
CRL	NULL
1552	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
antibiotics	NULL
.	NULL

Two	NULL
strains	NULL
of	NULL
HHV-6	NULL
were	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

HHV-6	NULL
(	NULL
GS	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

;	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
P.	NULL
Pellet	NULL
,	NULL
Centers	NULL
for	NULL
Disease	NULL
Control	NULL
,	NULL
Atlanta	NULL
,	NULL
Ga.	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
was	NULL
grown	NULL
in	NULL
HSB-2	NULL
cells	NULL
,	NULL
and	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
was	NULL
grown	NULL
in	NULL
Molt-3	NULL
cells	NULL
.	NULL

Infected	NULL
cells	NULL
were	NULL
collected	NULL
6	NULL
to	NULL
8	NULL
days	NULL
postinfection	NULL
when	NULL
more	NULL
than	NULL
80	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
positive	NULL
for	NULL
viral	NULL
antigens	NULL
in	NULL
an	NULL
indirect	NULL
immunofluorescence	NULL
assay	NULL
(	NULL
IFA	NULL
)	NULL
by	NULL
using	NULL
HHV-6	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
3	NULL
)	NULL
.	NULL

These	NULL
infected	NULL
cells	NULL
were	NULL
frozen	NULL
and	NULL
thawed	NULL
twice	NULL
,	NULL
and	NULL
the	NULL
50	NULL
%	NULL
tissue	NULL
culture	NULL
infectivity	NULL
dose	NULL
was	NULL
determined	NULL
by	NULL
procedures	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
,	NULL
41	NULL
)	NULL
on	NULL
HSB-2	NULL
cells	NULL
for	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
and	NULL
Molt-3	NULL
cells	NULL
for	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
.	NULL

Human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Fresh	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
purified	NULL
protein	NULL
derivative	NULL
(	NULL
PPD	NULL
)	NULL
-immune	NULL
,	NULL
normal	NULL
human	NULL
donors	NULL
by	NULL
using	NULL
Hy-paque-Ficoll	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
(	NULL
10°	NULL
per	NULL
well	NULL
)	NULL
were	NULL
then	NULL
stimulated	NULL
for	NULL
6	NULL
days	NULL
with	NULL
tuberculin	NULL
PPD	NULL
(	NULL
5	NULL
pl/ml	NULL
)	NULL
in	NULL
96-well	NULL
round-bottom	NULL
plates	NULL
.	NULL

Lymphoblasts	NULL
were	NULL
separated	NULL
from	NULL
small	NULL
mononuclear	NULL
cells	NULL
and	NULL
dead	NULL
cells	NULL
by	NULL
using	NULL
a	NULL
35	NULL
to	NULL
45	NULL
%	NULL
Percoll	NULL
step	NULL
gradient	NULL
.	NULL

The	NULL
cells	NULL
collected	NULL
at	NULL
the	NULL
interface	NULL
between	NULL
35	NULL
and	NULL
45	NULL
%	NULL
were	NULL
judged	NULL
to	NULL
be	NULL
>	NULL
98	NULL
%	NULL
lymphoblasts	NULL
by	NULL
microscopic	NULL
examination	NULL
.	NULL

By	NULL
immunofluorescence	NULL
,	NULL
85	NULL
to	NULL
89	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
judged	NULL
to	NULL
be	NULL
CD3+	NULL
(	NULL
Ortho	NULL
T3	NULL
antibody	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
are	NULL
referred	NULL
to	NULL
in	NULL
this	NULL
report	NULL
as	NULL
T-cell	NULL
lymphoblasts	NULL
and	NULL
were	NULL
used	NULL
for	NULL
transfections	NULL
.	NULL

Transfection	NULL
and	NULL
infection	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
T-cell	NULL
lymphoblasts	NULL
were	NULL
transfected	NULL
by	NULL
a	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
appropriate	NULL
DNA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
700	NULL
pg	NULL
of	NULL
DEAE-dextran	NULL
per	NULL
ml	NULL
was	NULL
added	NULL
to	NULL
T-cell	NULL
lymphoblasts	NULL
or	NULL
the	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
for	NULL
3	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
dimethyl	NULL
}	NULL
sulfoxide	NULL
(	NULL
10	NULL
%	NULL
)	NULL
for	NULL
exactly	NULL
1	NULL
min	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
placed	NULL
in	NULL
fresh	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
human	NULL
serum	NULL
.	NULL

A	NULL
portion	NULL
of	NULL
the	NULL
transfected	NULL
T	NULL
cells	NULL
was	NULL
then	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
or	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
0.01	NULL
by	NULL
incubating	NULL
the	NULL
T-cell	NULL
pellet	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
cell	NULL
lysates	NULL
of	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
or	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
.	NULL

In	NULL
certain	NULL
experiments	NULL
,	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clones	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
HIV	NULL
promoter	NULL
constructs	NULL
into	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
or	NULL
the	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
.	NULL

The	NULL
transfected	NULL
and/or	NULL
infected	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10*	NULL
per	NULL
well	NULL
)	NULL
were	NULL
then	NULL
added	NULL
to	NULL
either	NULL
irradiated	NULL
,	NULL
adherent	NULL
,	NULL
autologous	NULL
mononuclear	NULL
cells	NULL
(	NULL
10°	NULL
per	NULL
well	NULL
)	NULL
alone	NULL
or	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
incubated	NULL
overnight	NULL
with	NULL
tuberculin	NULL
PPD	NULL
(	NULL
5	NULL
J.	NULL
Viror	NULL
.	NULL

ul/ml	NULL
)	NULL
in	NULL
96-well	NULL
flat-bottom	NULL
plates	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
cell	NULL
populations	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
resting	NULL
transfected	NULL
T	NULL
cells	NULL
or	NULL
stimulated	NULL
transfected	NULL
T	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

Five	NULL
days	NULL
later	NULL
,	NULL
the	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
used	NULL
in	NULL
CAT	NULL
assays	NULL
.	NULL

Since	NULL
a	NULL
background	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
is	NULL
observed	NULL
in	NULL
fresh	NULL
T-cell	NULL
blasts	NULL
as	NULL
a	NULL
result	NULL
of	NULL
antigenic	NULL
stimulation	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
5	NULL
days	NULL
after	NULL
transfection	NULL
in	NULL
order	NULL
to	NULL
lower	NULL
this	NULL
background	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Transfected	NULL
T	NULL
cells	NULL
,	NULL
collected	NULL
after	NULL
5	NULL
days	NULL
,	NULL
were	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
sonication	NULL
buffer	NULL
(	NULL
0.25	NULL
M	NULL
Tris	NULL
HCl	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
number	NULL
was	NULL
adjusted	NULL
to	NULL
2	NULL
x	NULL
106/100	NULL
pl	NULL
so	NULL
that	NULL
the	NULL
same	NULL
number	NULL
of	NULL
cells	NULL
was	NULL
used	NULL
in	NULL
each	NULL
CAT	NULL
assay	NULL
.	NULL

Cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
single	NULL
freeze	NULL
(	NULL
-70°C	NULL
)	NULL
-thaw	NULL
(	NULL
37°C	NULL
)	NULL
cycle	NULL
and	NULL
1	NULL
min	NULL
of	NULL
sonication	NULL
,	NULL
followed	NULL
by	NULL
centrifugation	NULL
to	NULL
remove	NULL
cell	NULL
debris	NULL
.	NULL

CAT	NULL
assays	NULL
using	NULL
[	NULL
'*CJchloramphenicol	NULL
and	NULL
thin-layer	NULL
chromatography	NULL
have	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
previously	NULL
(	NULL
12	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
using	NULL
[	NULL
}	NULL
Hlacetyl	NULL
coenzyme	NULL
A	NULL
(	NULL
PHlacetyl-CoA	NULL
)	NULL
have	NULL
been	NULL
described	NULL
by	NULL
Neuman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
50	NULL
pl	NULL
of	NULL
the	NULL
cell	NULL
lysates	NULL
,	NULL
[	NULL
PHJacetyl-CoA	NULL
,	NULL
and	NULL
chloramphenicol	NULL
was	NULL
mixed	NULL
in	NULL
100	NULL
mM	NULL
Tris	NULL
HCI	NULL
,	NULL
pH	NULL
8.0	NULL
.	NULL

An	NULL
organic	NULL
scintillation	NULL
cocktail	NULL
(	NULL
Econofluor	NULL
;	NULL
Hewlett-Packard	NULL
)	NULL
was	NULL
layered	NULL
over	NULL
this	NULL
mix-ture	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
counted	NULL
in	NULL
a	NULL
beta	NULL
scintillation	NULL
counter	NULL
at	NULL
hourly	NULL
intervals	NULL
after	NULL
initiation	NULL
of	NULL
the	NULL
assay	NULL
.	NULL

Units	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
each	NULL
cell	NULL
lysate	NULL
were	NULL
calculated	NULL
according	NULL
to	NULL
a	NULL
standard	NULL
curve	NULL
established	NULL
with	NULL
a	NULL
CAT	NULL
sample	NULL
(	NULL
Pharmacia	NULL
)	NULL
of	NULL
known	NULL
enzymatic	NULL
activity	NULL
.	NULL

RESULTS	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
transactivates	NULL
the	NULL
HIV	NULL
LTR	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphoblasts	NULL
.	NULL

The	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
used	NULL
in	NULL
this	NULL
study	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
and	NULL
consist	NULL
of	NULL
approximately	NULL
85	NULL
%	NULL
CD3+	NULL
,	NULL
59	NULL
%	NULL
CD4+	NULL
,	NULL
and	NULL
32	NULL
%	NULL
CD8+	NULL
cells	NULL
.	NULL

These	NULL
lymphoblasts	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
HIV	NULL
CAT	NULL
construct	NULL
,	NULL
containing	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
by	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
was	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

Five	NULL
days	NULL
after	NULL
infection	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
,	NULL
30	NULL
to	NULL
40	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
reacted	NULL
with	NULL
HHV-6-specific	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
3	NULL
)	NULL
by	NULL
IFA	NULL
.	NULL

This	NULL
result	NULL
indicated	NULL
that	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
productively	NULL
infected	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
uninfected	NULL
lymphocytes	NULL
reacted	NULL
with	NULL
HHV-6-specific	NULL
monoclonal	NULL
antibodies	NULL
,	NULL
indicating	NULL
the	NULL
absence	NULL
of	NULL
endogenous	NULL
HHV-6	NULL
virus	NULL
.	NULL

After	NULL
5	NULL
days	NULL
in	NULL
culture	NULL
,	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
transfected	NULL
cells	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Lysates	NULL
from	NULL
transfected	NULL
T	NULL
cells	NULL
without	NULL
antigen	NULL
(	NULL
PPD	NULL
)	NULL
stimulation	NULL
and	NULL
without	NULL
HHV	NULL
-6	NULL
infection	NULL
converted	NULL
9	NULL
%	NULL
of	NULL
the	NULL
chloramphenicol	NULL
substrate	NULL
to	NULL
its	NULL
acetylated	NULL
forms	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
thin-layer	NULL
chromatography	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

This	NULL
lysate	NULL
contained	NULL
a	NULL
total	NULL
of	NULL
0.12	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Transfected	NULL
T-cell	NULL
blasts	NULL
activated	NULL
with	NULL
antigen	NULL
showed	NULL
higher	NULL
CAT	NULL
activity	NULL
than	NULL
did	NULL
unstimulated	NULL
T	NULL
cells	NULL
.	NULL

Lysates	NULL
from	NULL
these	NULL
cells	NULL
converted	NULL
79	NULL
%	NULL
of	NULL
the	NULL
chloramphenicol	NULL
to	NULL
its	NULL
acetylated	NULL
forms	NULL
and	NULL
contained	NULL
a	NULL
total	NULL
of	NULL
0.46	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

This	NULL
represents	NULL
a	NULL
fourfold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
after	NULL
antigenic	NULL
stimulation	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
confirm	NULL
our	NULL
previous	NULL
studies	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
antigen	NULL
activation	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
can	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Infection	NULL
of	NULL
these	NULL
transfected	NULL
T	NULL
cells	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
resulted	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
stimulated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

When	NULL
lysates	NULL
from	NULL
unstimulated	NULL
,	NULL
GS-infected	NULL
T-cell	NULL
lymphoblasts	NULL
were	NULL
tested	NULL
for	NULL
CAT	NULL
activity	NULL
,	NULL
there	NULL
was	NULL
a	NULL
conversion	NULL
of	NULL
75	NULL
%	NULL
of	NULL
the	NULL
Vor	NULL
.	NULL

65	NULL
,	NULL
1991	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
HIV	NULL
LTR	NULL
BY	NULL
HHV-6	NULL
2897	NULL
PPD	NULL
-	NULL
0	NULL
+0	NULL
0-0	NULL
+	NULL
HHV-6	NULL
-	NULL
=	NULL
+	NULL
+	NULL
-o	NULL
a	NULL
o	NULL
;	NULL
(	NULL
s	NULL
NF	NULL
al	NULL
ATIM	NULL
HOURS	NULL
OF	NULL
INCUBATION	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

CAT	NULL
enzymatic	NULL
activity	NULL
from	NULL
primary	NULL
T-cell	NULL
lysates	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Thin-layer	NULL
chromatography	NULL
of	NULL
[	NULL
'*C	NULL
)	NULL
chloramphenicol	NULL
reacted	NULL
with	NULL
cell	NULL
lysates	NULL
from	NULL
stimulated	NULL
T	NULL
cells	NULL
(	NULL
PPD+	NULL
)	NULL
and	NULL
resting	NULL
T	NULL
cells	NULL
(	NULL
PPD-	NULL
)	NULL
either	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
+	NULL
)	NULL
or	NULL
uninfected	NULL
(	NULL
-	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Standard	NULL
curve	NULL
of	NULL
CAT	NULL
enzymatic	NULL
activity	NULL
obtained	NULL
by	NULL
using	NULL
a	NULL
rapid	NULL
method	NULL
that	NULL
utilizes	NULL
[	NULL
'HJacetyl-CoA	NULL
.	NULL

This	NULL
standard	NULL
curve	NULL
is	NULL
used	NULL
to	NULL
calculate	NULL
the	NULL
amount	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

As	NULL
little	NULL
as	NULL
0.01	NULL
U	NULL
of	NULL
enzymatic	NULL
activity	NULL
can	NULL
be	NULL
detected	NULL
per	NULL
lysate	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CAT	NULL
activity	NULL
measured	NULL
in	NULL
T-cell	NULL
lysates	NULL
by	NULL
the	NULL
rapid	NULL
method	NULL
.	NULL

substrate	NULL
,	NULL
corresponding	NULL
to	NULL
0.64	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
,	NULL
while	NULL
lysates	NULL
from	NULL
activated	NULL
,	NULL
infected	NULL
T	NULL
cells	NULL
showed	NULL
a	NULL
99	NULL
%	NULL
conversion	NULL
of	NULL
the	NULL
substrate	NULL
and	NULL
2.61	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
values	NULL
represent	NULL
5-	NULL
and	NULL
22-fold	NULL
increases	NULL
in	NULL
CAT	NULL
activity	NULL
without	NULL
and	NULL
with	NULL
antigenic	NULL
stimulation	NULL
,	NULL
respectively	NULL
.	NULL

Since	NULL
CAT	NULL
assays	NULL
with	NULL
[	NULL
*HJacetyl-CoA	NULL
TABLE	NULL
1	NULL
.	NULL

Evidence	NULL
that	NULL
the	NULL
enhancer	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
is	NULL
required	NULL
for	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
transactivation	NULL
``	NULL
CAT	NULL
activity	NULL
(	NULL
total	NULL
U	NULL
in	NULL
cell	NULL
lysate	NULL
)	NULL
Promoter	NULL
dT-ccllb	NULL
Uninfected	NULL
cells	NULL
HHV-6-infected	NULL
cells	NULL
ono	NULL
-	NULL
+	NULL
-	NULL
+	NULL
HIV	NULL
CAT	NULL
1	NULL
0.12	NULL
-	NULL
0.45	NULL
(	NULL
4	NULL
)	NULL
-	NULL
0.78	NULL
(	NULL
7	NULL
)	NULL
3.04	NULL
(	NULL
25	NULL
)	NULL
2	NULL
0.12	NULL
-	NULL
0.45	NULL
(	NULL
4	NULL
)	NULL
0.64	NULL
(	NULL
5	NULL
)	NULL
2.61	NULL
(	NULL
22	NULL
)	NULL
-147	NULL
CAT	NULL
1	NULL
0.24	NULL
1.11	NULL
(	NULL
5	NULL
)	NULL
2.97	NULL
(	NULL
12	NULL
)	NULL
3.84	NULL
(	NULL
16	NULL
)	NULL
2	NULL
0.19	NULL
1.08	NULL
(	NULL
6	NULL
)	NULL
2.08	NULL
(	NULL
11	NULL
)	NULL
-	NULL
3.24	NULL
(	NULL
17	NULL
)	NULL
3	NULL
0.16	NULL
-	NULL
0.31	NULL
(	NULL
2	NULL
)	NULL
1.49	NULL
(	NULL
9	NULL
)	NULL
2.32	NULL
(	NULL
15	NULL
)	NULL
-57	NULL
CAT	NULL
1	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
0.05	NULL
0.05	NULL
2	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
0.03	NULL
0.04	NULL
Mutant	NULL
NF	NULL
«	NULL
B-	NULL
2	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
CAT	NULL
3	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
``	NULL
Various	NULL
promoters	NULL
were	NULL
transfected	NULL
into	NULL
primary	NULL
T	NULL
cells	NULL
by	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
either	NULL
cultured	NULL
directly	NULL
with	NULL
autologous	NULL
,	NULL
irradiated	NULL
mononuclear	NULL
cells	NULL
or	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
and	NULL
then	NULL
added	NULL
to	NULL
feeder	NULL
cells	NULL
.	NULL

Antigen	NULL
was	NULL
then	NULL
added	NULL
to	NULL
appropriate	NULL
cultures	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
days	NULL
,	NULL
collected	NULL
,	NULL
and	NULL
lysed	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
at	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
0.01	NULL
.	NULL

Some	NULL
cell	NULL
cultures	NULL
were	NULL
given	NULL
the	NULL
antigen	NULL
PPD	NULL
(	NULL
+	NULL
)	NULL
,	NULL
while	NULL
others	NULL
were	NULL
given	NULL
medium	NULL
(	NULL
-	NULL
)	NULL
.	NULL

*	NULL
Cells	NULL
from	NULL
at	NULL
least	NULL
two	NULL
different	NULL
donors	NULL
were	NULL
transfected	NULL
with	NULL
each	NULL
promoter	NULL
.	NULL

Cells	NULL
from	NULL
each	NULL
donor	NULL
were	NULL
transfected	NULL
twice	NULL
.	NULL

©	NULL
Values	NULL
in	NULL
parentheses	NULL
represent	NULL
the	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
based	NULL
on	NULL
the	NULL
enzymatic	NULL
activity	NULL
found	NULL
in	NULL
noninfected	NULL
,	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

are	NULL
more	NULL
quantitative	NULL
and	NULL
convenient	NULL
(	NULL
30	NULL
)	NULL
,	NULL
subsequent	NULL
cell	NULL
lysates	NULL
were	NULL
all	NULL
measured	NULL
by	NULL
this	NULL
rapid	NULL
method	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
infection	NULL
of	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
activates	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
stimulated	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
activation	NULL
in	NULL
resting	NULL
cells	NULL
is	NULL
not	NULL
as	NULL
pronounced	NULL
(	NULL
5-	NULL
to	NULL
7-fold	NULL
)	NULL
as	NULL
in	NULL
antigen-activated	NULL
T	NULL
cells	NULL
(	NULL
22-	NULL
to	NULL
25-fold	NULL
)	NULL
,	NULL
the	NULL
data	NULL
clearly	NULL
demonstrate	NULL
that	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
can	NULL
infect	NULL
unstimulated	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
will	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
which	NULL
otherwise	NULL
remains	NULL
quiescent	NULL
.	NULL

Although	NULL
activation	NULL
of	NULL
resting	NULL
,	NULL
primary	NULL
T	NULL
cells	NULL
by	NULL
HHV-6	NULL
may	NULL
have	NULL
also	NULL
contributed	NULL
to	NULL
the	NULL
low	NULL
level	NULL
of	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
this	NULL
alone	NULL
can	NULL
not	NULL
account	NULL
for	NULL
all	NULL
of	NULL
the	NULL
transactivation	NULL
activity	NULL
observed	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
antigen-activated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
by	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
.	NULL

Soon	NULL
after	NULL
the	NULL
GS	NULL
strain	NULL
of	NULL
HHV-6	NULL
was	NULL
identified	NULL
,	NULL
a	NULL
new	NULL
variant	NULL
strain	NULL
of	NULL
HHV-6	NULL
was	NULL
identified	NULL
which	NULL
was	NULL
designated	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
(	NULL
5	NULL
)	NULL
.	NULL

HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
is	NULL
related	NULL
to	NULL
the	NULL
GS	NULL
strain	NULL
both	NULL
antigenically	NULL
and	NULL
genetically	NULL
(	NULL
17	NULL
,	NULL
25	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Both	NULL
strains	NULL
infect	NULL
human	NULL
T	NULL
lymphocytes	NULL
but	NULL
seem	NULL
to	NULL
have	NULL
a	NULL
preference	NULL
for	NULL
distinct	NULL
subsets	NULL
.	NULL

These	NULL
subsets	NULL
are	NULL
still	NULL
not	NULL
clearly	NULL
defined	NULL
.	NULL

The	NULL
Z29	NULL
strain	NULL
can	NULL
effectively	NULL
infect	NULL
the	NULL
Molt-3	NULL
T-cell	NULL
line	NULL
but	NULL
not	NULL
HSB-2	NULL
,	NULL
while	NULL
the	NULL
GS	NULL
strain	NULL
infects	NULL
HSB-2	NULL
but	NULL
not	NULL
Molt-3	NULL
.	NULL

Both	NULL
HHV-6	NULL
strains	NULL
can	NULL
infect	NULL
primary	NULL
human	NULL
phtyohemag-glutinin-stimulated	NULL
blasts	NULL
,	NULL
but	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
failed	NULL
to	NULL
replicate	NULL
in	NULL
unstimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
specific	NULL
for	NULL
the	NULL
antigen	NULL
tuberculin	NULL
PPD	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
HIV	NULL
CAT	NULL
construct	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
.	NULL

After	NULL
6	NULL
days	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
tested	NULL
for	NULL
infection	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
by	NULL
IFA	NULL
using	NULL
cross-reactive	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
41	NULL
)	NULL
.	NULL

T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PPD	NULL
during	NULL
the	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
infection	NULL
had	NULL
enlarged	NULL
cells	NULL
and	NULL
were	NULL
pos-	NULL
2898	NULL
HORVAT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
DONOR	NULL
2	NULL
5.0	NULL
a	NULL
(	NULL
48x	NULL
)	NULL
#	NULL
-	NULL
40	NULL
§	NULL
5	NULL
3.0	NULL
E	NULL
2.0	NULL
(	NULL
199	NULL
§	NULL
io	NULL
0.0	NULL
Antigen	NULL
:	NULL
Ce	NULL
Sine	NULL
a	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
:	NULL
-o-	NULL
fp	NULL
of	NULL
B	NULL
DONOR	NULL
4	NULL
5.0	NULL
gao	NULL
)	NULL
g	NULL
4.0	NULL
3	NULL
3.0	NULL
E	NULL
2.0	NULL
p40	NULL
3	NULL
1.0	NULL
0.0	NULL
Antigen	NULL
:	NULL
-	NULL
oof	NULL
o-	NULL
+	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
:	NULL
ai	NULL
e-	NULL
cfp	NULL
+	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Total	NULL
CAT	NULL
activity	NULL
from	NULL
resting	NULL
(	NULL
-	NULL
)	NULL
and	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cells	NULL
either	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
(	NULL
+	NULL
)	NULL
or	NULL
left	NULL
uninfected	NULL
(	NULL
-	NULL
)	NULL
.	NULL

Shown	NULL
are	NULL
representative	NULL
results	NULL
from	NULL
two	NULL
different	NULL
donors	NULL
;	NULL
the	NULL
values	NULL
in	NULL
parentheses	NULL
show	NULL
the	NULL
increase	NULL
in	NULL
total	NULL
CAT	NULL
activity	NULL
compared	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
unstimulated	NULL
T	NULL
lymphoblasts	NULL
.	NULL

The	NULL
total	NULL
units	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
are	NULL
0.09	NULL
for	NULL
donor	NULL
2	NULL
and	NULL
0.011	NULL
for	NULL
donor	NULL
4.	NULL
itive	NULL
for	NULL
viral	NULL
antigens	NULL
.	NULL

However	NULL
,	NULL
T	NULL
cells	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
stimulation	NULL
showed	NULL
no	NULL
viral	NULL
antigen-positive	NULL
cells	NULL
.	NULL

After	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
transfected	NULL
T	NULL
lymphocytes	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
lysed	NULL
,	NULL
and	NULL
the	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
from	NULL
the	NULL
cell	NULL
lysates	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
HIV	NULL
CAT	NULL
promoter	NULL
was	NULL
activated	NULL
only	NULL
in	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
-infected	NULL
human	NULL
T	NULL
lymphocytes	NULL
that	NULL
had	NULL
been	NULL
stimulated	NULL
with	NULL
antigen	NULL
.	NULL

This	NULL
was	NULL
explained	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
productive	NULL
infections	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
IFA	NULL
with	NULL
HHV-6-specific	NULL
antibodies	NULL
,	NULL
occurred	NULL
only	NULL
in	NULL
cells	NULL
stimulated	NULL
by	NULL
antigen	NULL
.	NULL

Unstimulated	NULL
cells	NULL
did	NULL
not	NULL
support	NULL
viral	NULL
infection	NULL
,	NULL
nor	NULL
did	NULL
they	NULL
demonstrate	NULL
HIV	NULL
CAT	NULL
promoter	NULL
activation	NULL
(	NULL
0.09	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
donor	NULL
2	NULL
;	NULL
0.011	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
donor	NULL
4	NULL
)	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
not	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
,	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
activated	NULL
by	NULL
antigenic	NULL
stimulation	NULL
(	NULL
19-fold	NULL
in	NULL
donor	NULL
2	NULL
,	NULL
with	NULL
1.75	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
;	NULL
140-fold	NULL
in	NULL
donor	NULL
4	NULL
,	NULL
with	NULL
1.54	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

When	NULL
the	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
observed	NULL
(	NULL
0.97-fold	NULL
in	NULL
donor	NULL
2	NULL
,	NULL
with	NULL
0.087	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
;	NULL
0.7-fold	NULL
in	NULL
donor	NULL
4	NULL
,	NULL
with	NULL
0.008	NULL
U	NULL
of	NULL
CAT	NULL
activity	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
and	NULL
activated	NULL
with	NULL
PPD	NULL
,	NULL
a	NULL
46-	NULL
to	NULL
404-fold	NULL
increase	NULL
in	NULL
total	NULL
CAT	NULL
activity	NULL
and	NULL
J.	NULL
Viror	NULL
.	NULL

us	NULL
+1	NULL
R	NULL
NEG	NULL
reg	NULL
NF	NULL
kB	NULL
tai	NULL
.	NULL

target	NULL
TATA	NULL
¥	NULL
ory	NULL
Ava	NULL
l	NULL
L———|	NULL
sites	NULL
{	NULL
nm	NULL
CAT	NULL
~57	NULL
+80	NULL
l	NULL
=	NULL
-147	NULL
CAT	NULL
-14	NULL
?	NULL

+80	NULL
=	NULL
/	NULL
\	NULL
i	NULL
Mutant	NULL
-642	NULL
e	NULL
NF	NULL
kB	NULL
Cc	NULL
co	NULL
|	NULL
|	NULL
-	NULL
intact	NULL
I	NULL
HIV	NULL
CAT	NULL
-642	NULL
+80	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
the	NULL
HIV	NULL
promoters	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

-57	NULL
CAT	NULL
contained	NULL
only	NULL
one	NULL
Spl	NULL
site	NULL
and	NULL
the	NULL
TATA	NULL
box	NULL
as	NULL
well	NULL
as	NULL
the	NULL
rat	NULL
target	NULL
sequences	NULL
.	NULL

The	NULL
-147	NULL
CAT	NULL
plasmid	NULL
contained	NULL
the	NULL
NFB	NULL
site	NULL
,	NULL
all	NULL
of	NULL
the	NULL
Sp1	NULL
sites	NULL
,	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
the	NULL
tat	NULL
target	NULL
region	NULL
but	NULL
had	NULL
lost	NULL
the	NULL
negative	NULL
regulatory	NULL
region	NULL
(	NULL
NEG	NULL
reg	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
NFB	NULL
promoter	NULL
had	NULL
all	NULL
regulatory	NULL
regions	NULL
intact	NULL
but	NULL
had	NULL
two	NULL
regions	NULL
within	NULL
the	NULL
NFxB	NULL
site	NULL
changed	NULL
from	NULL
GGG	NULL
to	NULL
TCT	NULL
.	NULL

The	NULL
intact	NULL
HIV	NULL
CAT	NULL
promoter	NULL
had	NULL
no	NULL
sequence	NULL
changed	NULL
or	NULL
deleted	NULL
.	NULL

3-fold	NULL
increase	NULL
in	NULL
activity	NULL
over	NULL
antigenic	NULL
stimulation	NULL
alone	NULL
were	NULL
noted	NULL
(	NULL
4.18	NULL
U	NULL
of	NULL
total	NULL
CAT	NULL
activity	NULL
in	NULL
donor	NULL
2	NULL
;	NULL
4.44	NULL
U	NULL
of	NULL
total	NULL
CAT	NULL
activity	NULL
in	NULL
donor	NULL
4	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
transactivated	NULL
the	NULL
HIV	NULL
LTR	NULL
in	NULL
antigen-stimu-lated	NULL
,	NULL
primary	NULL
,	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
that	NULL
transactivation	NULL
by	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
requires	NULL
productive	NULL
infection	NULL
of	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
depends	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
functional	NULL
NFB	NULL
enhancer	NULL
site	NULL
.	NULL

Earlier	NULL
studies	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
showed	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
influenced	NULL
by	NULL
the	NULL
NFB	NULL
enhancer	NULL
region	NULL
as	NULL
well	NULL
as	NULL
an	NULL
upstream	NULL
region	NULL
that	NULL
exerts	NULL
negative	NULL
regulation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Several	NULL
different	NULL
constructs	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
were	NULL
transfected	NULL
into	NULL
PPD-specific	NULL
human	NULL
T	NULL
lymphoblasts	NULL
.	NULL

The	NULL
HIV	NULL
promoter	NULL
designated	NULL
-57	NULL
CAT	NULL
contains	NULL
one	NULL
of	NULL
the	NULL
Spl	NULL
sites	NULL
as	NULL
well	NULL
as	NULL
the	NULL
TATA	NULL
site	NULL
.	NULL

This	NULL
promoter	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
active	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
(	NULL
COS-7	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
but	NULL
little	NULL
or	NULL
no	NULL
promoter	NULL
activity	NULL
has	NULL
ever	NULL
been	NULL
observed	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
(	NULL
13	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
promoter	NULL
designated	NULL
-147	NULL
CAT	NULL
retained	NULL
the	NULL
NFB	NULL
binding	NULL
region	NULL
as	NULL
well	NULL
as	NULL
the	NULL
three	NULL
Spl	NULL
sites	NULL
and	NULL
the	NULL
TATA	NULL
box	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
promoter	NULL
does	NULL
not	NULL
have	NULL
the	NULL
negative	NULL
regulatory	NULL
region	NULL
,	NULL
and	NULL
therefore	NULL
the	NULL
CAT	NULL
activity	NULL
expressed	NULL
after	NULL
transfection	NULL
into	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
is	NULL
somewhat	NULL
higher	NULL
than	NULL
with	NULL
the	NULL
intact	NULL
promoter	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

T	NULL
lymphoblasts	NULL
transfected	NULL
with	NULL
-147	NULL
CAT	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
consistently	NULL
showed	NULL
evidence	NULL
of	NULL
transactivation	NULL
(	NULL
9-	NULL
to	NULL
17-fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
indicates	NULL
that	NULL
the	NULL
negative	NULL
regulatory	NULL
region	NULL
is	NULL
not	NULL
primarily	NULL
involved	NULL
in	NULL
the	NULL
increased	NULL
promoter	NULL
activity	NULL
due	NULL
to	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
.	NULL

These	NULL
results	NULL
also	NULL
show	NULL
that	NULL
the	NULL
DNA	NULL
sequences	NULL
responsible	NULL
for	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
transactivation	NULL
must	NULL
be	NULL
within	NULL
the	NULL
-147	NULL
to	NULL
-57	NULL
region	NULL
.	NULL

To	NULL
further	NULL
locate	NULL
the	NULL
specific	NULL
promoter	NULL
region	NULL
responsible	NULL
for	NULL
HHV-6	NULL
transactivation	NULL
,	NULL
the	NULL
HIV	NULL
LTR	NULL
plasmid	NULL
containing	NULL
a	NULL
mutated	NULL
NFB	NULL
CAT	NULL
promoter	NULL
was	NULL
transfected	NULL
into	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

This	NULL
promoter	NULL
contained	NULL
two	NULL
sequences	NULL
Vor	NULL
.	NULL

65	NULL
,	NULL
1991	NULL
TABLE	NULL
2	NULL
.	NULL

Evidence	NULL
that	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
plasmids	NULL
can	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
``	NULL
CAT	NULL
activity	NULL
(	NULL
total	NULL
U	NULL
in	NULL
cell	NULL
lysate	NULL
)	NULL
HIV-CAT	NULL
HIV-CAT	NULL
+	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
plasmid	NULL
Amiga	NULL
“	NULL
:	NULL
Antigenic	NULL
stimulation	NULL
3	NULL
”	NULL
;	NULL
le	NULL
stimulation	NULL
Plasmid	NULL
ha	NULL
o	NULL
-	NULL
+	NULL
-	NULL
+	NULL
2	NULL
0.04	NULL
1.8	NULL
(	NULL
45	NULL
)	NULL
pZVB70	NULL
4.05	NULL
(	NULL
101	NULL
)	NULL
10.84	NULL
(	NULL
271	NULL
)	NULL
3	NULL
0.12	NULL
-	NULL
0.26	NULL
(	NULL
2	NULL
)	NULL
4.54	NULL
(	NULL
38	NULL
)	NULL
10.88	NULL
(	NULL
91	NULL
)	NULL
3	NULL
0.15	NULL
1.95	NULL
(	NULL
13	NULL
)	NULL
3.85	NULL
(	NULL
26	NULL
)	NULL
11.55	NULL
(	NULL
77	NULL
)	NULL
2	NULL
0.1	NULL
1.24	NULL
(	NULL
12	NULL
)	NULL
pZVH14	NULL
1.77	NULL
(	NULL
18	NULL
)	NULL
2.58	NULL
(	NULL
26	NULL
)	NULL
3	NULL
0.24	NULL
1.95	NULL
(	NULL
8	NULL
)	NULL
2.37	NULL
(	NULL
10	NULL
)	NULL
3.14	NULL
(	NULL
13	NULL
)	NULL
3	NULL
0.19	NULL
1.46	NULL
(	NULL
8	NULL
)	NULL
1.77	NULL
(	NULL
9	NULL
)	NULL
2.87	NULL
(	NULL
15	NULL
)	NULL
1	NULL
0.02	NULL
1.35	NULL
(	NULL
68	NULL
)	NULL
pZVB10	NULL
0.26	NULL
(	NULL
13	NULL
)	NULL
1.68	NULL
(	NULL
84	NULL
)	NULL
4	NULL
0.01	NULL
1.54	NULL
(	NULL
154	NULL
)	NULL
0.35	NULL
(	NULL
35	NULL
)	NULL
1.83	NULL
(	NULL
183	NULL
)	NULL
1	NULL
0.02	NULL
1.7	NULL
(	NULL
85	NULL
)	NULL
pZVB9	NULL
0.02	NULL
1.12	NULL
(	NULL
56	NULL
)	NULL
3	NULL
0.24	NULL
1.95	NULL
(	NULL
8	NULL
)	NULL
0.17	NULL
1.51	NULL
(	NULL
6	NULL
)	NULL
3	NULL
0.38	NULL
1.91	NULL
(	NULL
5	NULL
)	NULL
pZVB15	NULL
0.07	NULL
2.79	NULL
(	NULL
7	NULL
)	NULL
4	NULL
0.01	NULL
1.54	NULL
(	NULL
154	NULL
)	NULL
0.05	NULL
(	NULL
5	NULL
)	NULL
1.87	NULL
(	NULL
187	NULL
)	NULL
2	NULL
0.1	NULL
1.24	NULL
(	NULL
12	NULL
)	NULL
pZV	NULL
B43	NULL
0.17	NULL
(	NULL
2	NULL
)	NULL
1.37	NULL
(	NULL
14	NULL
)	NULL
3	NULL
0.15	NULL
1.95	NULL
(	NULL
13	NULL
)	NULL
0.14	NULL
(	NULL
1	NULL
)	NULL
1.63	NULL
(	NULL
11	NULL
)	NULL
3	NULL
0.19	NULL
1.46	NULL
(	NULL
8	NULL
)	NULL
0.18	NULL
(	NULL
1	NULL
)	NULL
1.69	NULL
(	NULL
9	NULL
)	NULL
*	NULL
Plasmids	NULL
containing	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
were	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
into	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
after	NULL
5	NULL
days	NULL
from	NULL
cell	NULL
lysate	NULL
.	NULL

Antigen	NULL
activation	NULL
of	NULL
transfected	NULL
cells	NULL
was	NULL
as	NULL
described	NULL
for	NULL
Table	NULL
1	NULL
.	NULL

®	NULL
See	NULL
Table	NULL
1	NULL
,	NULL
footnote	NULL
c.	NULL
within	NULL
the	NULL
NFB	NULL
sites	NULL
that	NULL
had	NULL
been	NULL
changed	NULL
from	NULL
GGG	NULL
to	NULL
CTC	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
changes	NULL
that	NULL
in	NULL
the	NULL
NFB	NULL
site	NULL
eliminate	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
by	NULL
the	NULL
NFB	NULL
protein	NULL
(	NULL
27	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
in	NULL
the	NULL
NFKB	NULL
sites	NULL
abolished	NULL
the	NULL
HIV	NULL
promoter	NULL
activity	NULL
induced	NULL
in	NULL
primary	NULL
T	NULL
lymphoblasts	NULL
both	NULL
by	NULL
antigen	NULL
and	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
.	NULL

Although	NULL
no	NULL
CAT	NULL
activity	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
lysates	NULL
from	NULL
these	NULL
cells	NULL
,	NULL
IFA	NULL
indicated	NULL
that	NULL
the	NULL
population	NULL
of	NULL
T	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
mutant	NULL
NFB	NULL
promoter	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
contained	NULL
enlarged	NULL
cells	NULL
highly	NULL
positive	NULL
for	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
proteins	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
result	NULL
showed	NULL
that	NULL
the	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
productively	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
and	NULL
suggests	NULL
that	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
requires	NULL
the	NULL
NFB	NULL
region	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

At	NULL
least	NULL
three	NULL
different	NULL
DNA	NULL
segments	NULL
cloned	NULL
from	NULL
the	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
genome	NULL
can	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
when	NULL
cotransfected	NULL
into	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
genome	NULL
was	NULL
digested	NULL
with	NULL
the	NULL
restriction	NULL
enzyme	NULL
BamHI	NULL
or	NULL
HindIII	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
fragments	NULL
were	NULL
ligated	NULL
into	NULL
the	NULL
Bluescript	NULL
vector	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Six	NULL
different	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
fragments	NULL
representing	NULL
about	NULL
40	NULL
%	NULL
of	NULL
the	NULL
total	NULL
viral	NULL
genome	NULL
and	NULL
varying	NULL
in	NULL
length	NULL
from	NULL
3.3	NULL
to	NULL
21.4	NULL
kb	NULL
(	NULL
17	NULL
)	NULL
were	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

Each	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
fragment	NULL
was	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
into	NULL
the	NULL
primary	NULL
T-cell	NULL
populations	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cell	NULL
lysates	NULL
5	NULL
days	NULL
later	NULL
.	NULL

The	NULL
largest	NULL
fragment	NULL
,	NULL
pZVB70	NULL
(	NULL
21.4	NULL
kb	NULL
)	NULL
,	NULL
showed	NULL
a	NULL
dramatic	NULL
transactivating	NULL
effect	NULL
on	NULL
the	NULL
HIV	NULL
promoter	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
,	NULL
this	NULL
fragment	NULL
increased	NULL
HIV	NULL
promoter	NULL
activity	NULL
26	NULL
to	NULL
101	NULL
times	NULL
over	NULL
the	NULL
activity	NULL
expressed	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
.	NULL

When	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
antigen	NULL
,	NULL
there	NULL
was	NULL
a	NULL
77-	NULL
to	NULL
271-fold	NULL
increase	NULL
in	NULL
total	NULL
CAT	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
6-to	NULL
42-fold	NULL
over	NULL
the	NULL
antigenic	NULL
stimulation	NULL
alone	NULL
.	NULL

It	NULL
was	NULL
the	NULL
major	NULL
DNA	NULL
fragment	NULL
from	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
that	NULL
showed	NULL
this	NULL
level	NULL
of	NULL
activity	NULL
,	NULL
and	NULL
as	NULL
such	NULL
it	NULL
was	NULL
designated	NULL
a	NULL
high	NULL
transactivator	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

Two	NULL
other	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
fragments	NULL
,	NULL
designated	NULL
pZVH14	NULL
and	NULL
pZVB10	NULL
,	NULL
marginally	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
HIV	NULL
LTR	NULL
BY	NULL
HHV-6	NULL
2899	NULL
J	NULL
>	NULL
HIV-CAT	NULL
mutant	NULL
NFKB-CAT	NULL
4A	NULL
a	NULL
_	NULL
a	NULL
A	NULL
&	NULL
n	NULL
&	NULL
N	NULL
CAT	NULL
ACTIVITY	NULL
(	NULL
total	NULL
units	NULL
)	NULL
N	NULL
ta	NULL
CAT	NULL
ACTIVITY	NULL
(	NULL
total	NULL
units	NULL
)	NULL
LJ	NULL
t	NULL
L	NULL
o	NULL
-	NULL
GS	NULL
870	NULL
H14	NULL
B10	NULL
B43	NULL
-	NULL
Gs	NULL
B70	NULL
H14	NULL
810	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Total	NULL
CAT	NULL
activity	NULL
from	NULL
transfected	NULL
HSB-2	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
HIV	NULL
CAT	NULL
only	NULL
(	NULL
-	NULL
)	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
and	NULL
various	NULL
HHV-6	NULL
cloned	NULL
DNA	NULL
fragments	NULL
:	NULL
pZVB70	NULL
(	NULL
B70	NULL
)	NULL
,	NULL
pZVH14	NULL
(	NULL
H14	NULL
)	NULL
,	NULL
pZVB10	NULL
(	NULL
B10	NULL
)	NULL
,	NULL
and	NULL
pZVB43	NULL
(	NULL
B43	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HSB-2	NULL
cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
mutant	NULL
NFkB	NULL
CAT	NULL
plasmid	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
,	NULL
while	NULL
others	NULL
were	NULL
left	NULL
uninfected	NULL
(	NULL
-	NULL
)	NULL
.	NULL

A	NULL
portion	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
various	NULL
HHV-6	NULL
DNA	NULL
clones	NULL
as	NULL
described	NULL
above	NULL
.	NULL

(	NULL
Table	NULL
2	NULL
)	NULL
when	NULL
expressed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
stimulation	NULL
.	NULL

The	NULL
DNA	NULL
clone	NULL
pZVH14	NULL
contained	NULL
a	NULL
8.7-kb	NULL
fragment	NULL
from	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
,	NULL
while	NULL
clone	NULL
pZVB10	NULL
contained	NULL
a	NULL
6.2-kb	NULL
fragment	NULL
.	NULL

Since	NULL
these	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clones	NULL
showed	NULL
only	NULL
low-level	NULL
activation	NULL
of	NULL
HIV	NULL
CAT	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
and	NULL
promoter	NULL
activity	NULL
in	NULL
antigen-stimulated	NULL
cells	NULL
increased	NULL
only	NULL
slightly	NULL
,	NULL
we	NULL
have	NULL
designated	NULL
these	NULL
clones	NULL
low	NULL
transac-tivators	NULL
.	NULL

The	NULL
highest	NULL
transactivation	NULL
was	NULL
observed	NULL
when	NULL
cotransfected	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
antigen	NULL
,	NULL
suggesting	NULL
an	NULL
additive	NULL
effect	NULL
of	NULL
antigenic	NULL
stimulation	NULL
and	NULL
the	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
gene	NULL
product	NULL
(	NULL
s	NULL
)	NULL
on	NULL
HIV	NULL
promoter	NULL
activity	NULL
.	NULL

Table	NULL
2	NULL
also	NULL
shows	NULL
data	NULL
for	NULL
three	NULL
fragments	NULL
cloned	NULL
from	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
that	NULL
failed	NULL
to	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

These	NULL
DNA	NULL
clones	NULL
were	NULL
designated	NULL
pZVB9	NULL
(	NULL
11.8-kb	NULL
fragment	NULL
)	NULL
,	NULL
pZVB43	NULL
(	NULL
8.3-kb	NULL
fragment	NULL
)	NULL
,	NULL
and	NULL
pZVB15	NULL
(	NULL
3.3-kb	NULL
fragment	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
it	NULL
can	NULL
be	NULL
concluded	NULL
that	NULL
HHV-6	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
different	NULL
gene	NULL
segments	NULL
that	NULL
can	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
data	NULL
observed	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
,	NULL
these	NULL
fragments	NULL
were	NULL
also	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
into	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
demonstrated	NULL
(	NULL
14	NULL
)	NULL
,	NULL
infection	NULL
of	NULL
the	NULL
transfected	NULL
HSB-2	NULL
cells	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
(	NULL
threefold	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
also	NULL
transactivated	NULL
in	NULL
a	NULL
T-cell	NULL
line	NULL
.	NULL

Cotransfection	NULL
of	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clone	NULL
pZVB70	NULL
and	NULL
HIV	NULL
CAT	NULL
resulted	NULL
in	NULL
a	NULL
dramatic	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
(	NULL
58-fold	NULL
;	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Plasmid	NULL
pZVB70	NULL
transactivated	NULL
HIV	NULL
CAT	NULL
to	NULL
a	NULL
much	NULL
greater	NULL
extent	NULL
than	NULL
did	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

It	NULL
was	NULL
also	NULL
observed	NULL
that	NULL
plasmid	NULL
pZVH14	NULL
,	NULL
when	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
into	NULL
the	NULL
HSB-2	NULL
T-cell	NULL
line	NULL
,	NULL
activated	NULL
promoter	NULL
activity	NULL
to	NULL
a	NULL
higher	NULL
level	NULL
than	NULL
did	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

The	NULL
CAT	NULL
activity	NULL
in	NULL
these	NULL
samples	NULL
increased	NULL
30-fold	NULL
over	NULL
the	NULL
activity	NULL
of	NULL
HSB-2	NULL
cells	NULL
transfected	NULL
with	NULL
HIV	NULL
CAT	NULL
alone	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
during	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
,	NULL
the	NULL
gene	NULL
products	NULL
from	NULL
these	NULL
DNA	NULL
segments	NULL
are	NULL
under	NULL
some	NULL
type	NULL
of	NULL
regulation	NULL
that	NULL
is	NULL
lost	NULL
when	NULL
the	NULL
genes	NULL
are	NULL
cloned	NULL
into	NULL
plasmids	NULL
.	NULL

Cotransfection	NULL
of	NULL
HSB-2	NULL
cells	NULL
with	NULL
two	NULL
other	NULL
HHV-6	NULL
fragments	NULL
,	NULL
pZVB10	NULL
and	NULL
pZV	NULL
B43	NULL
,	NULL
did	NULL
not	NULL
show	NULL
any	NULL
transactivation	NULL
of	NULL
HIV	NULL
CAT	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
our	NULL
observation	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
,	NULL
that	NULL
the	NULL
gene	NULL
segments	NULL
contained	NULL
in	NULL
plasmids	NULL
pZVB70	NULL
and	NULL
pZVH14	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
;	NULL
however	NULL
,	NULL
unlike	NULL
the	NULL
situation	NULL
2900	NULL
HORVAT	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
3	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
mutant	NULL
NFB	NULL
promoter	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clones	NULL
``	NULL
CAT	NULL
activity	NULL
(	NULL
total	NULL
U	NULL
)	NULL
Mutant	NULL
NFkB	NULL
+	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
plasmid	NULL
Mutant	NULL
NFkB	NULL
T-cell	NULL
Antigen	NULL
stimulation	NULL
.	NULL

Antigenic	NULL
stimulation	NULL
donor	NULL
-__-	NULL
Plasmid	NULL
--	NULL
--	NULL
_______	NULL
-	NULL
+	NULL
-	NULL
+	NULL
3	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
pZVH14	NULL
0.07	NULL
(	NULL
7	NULL
)	NULL
0.07	NULL
(	NULL
7	NULL
)	NULL
2	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
0.04	NULL
(	NULL
4	NULL
)	NULL
0.06	NULL
(	NULL
6	NULL
)	NULL
2	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
pZVB70	NULL
-	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
3	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
2	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
pZVBI0	NULL
-	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
4	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
<	NULL
0.01	NULL
``	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clones	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
mutant	NULL
NFkB	NULL
promoter	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
into	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
days	NULL
as	NULL
described	NULL
for	NULL
Table	NULL
1	NULL
.	NULL

Total	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

*	NULL
See	NULL
Table	NULL
1	NULL
,	NULL
footnote	NULL
c.	NULL
for	NULL
primary	NULL
T	NULL
cells	NULL
,	NULL
pZVB10	NULL
failed	NULL
to	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
HSB-2	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
mutations	NULL
in	NULL
the	NULL
NFB	NULL
site	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
affected	NULL
the	NULL
transactivation	NULL
by	NULL
cloned	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
fragments	NULL
,	NULL
the	NULL
three	NULL
transactivating	NULL
fragments	NULL
were	NULL
cotransfected	NULL
into	NULL
primary	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
promoter	NULL
containing	NULL
the	NULL
NFkB	NULL
mutation	NULL
.	NULL

The	NULL
resulting	NULL
promoter	NULL
activities	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

Mutation	NULL
in	NULL
the	NULL
NFkB	NULL
site	NULL
completely	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
pZVB70	NULL
and	NULL
pZVB10	NULL
clones	NULL
to	NULL
transactivate	NULL
.	NULL

However	NULL
,	NULL
with	NULL
the	NULL
pZVH14	NULL
clone	NULL
,	NULL
a	NULL
slight	NULL
but	NULL
consistent	NULL
transactivation	NULL
was	NULL
observed	NULL
(	NULL
four-	NULL
to	NULL
sevenfold	NULL
)	NULL
that	NULL
was	NULL
less	NULL
than	NULL
the	NULL
transactivation	NULL
seen	NULL
with	NULL
the	NULL
intact	NULL
HIV	NULL
promoter	NULL
.	NULL

The	NULL
transactivation	NULL
of	NULL
the	NULL
mutated	NULL
NFkB	NULL
promoter	NULL
by	NULL
pZVH14	NULL
was	NULL
not	NULL
dependent	NULL
on	NULL
antigenic	NULL
stimulation	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
,	NULL
since	NULL
it	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
antigen	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
when	NULL
these	NULL
cloned	NULL
DNA	NULL
fragments	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
mutated	NULL
NFB	NULL
promoter	NULL
into	NULL
HSB-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
two	NULL
DNA	NULL
clones	NULL
,	NULL
pZVB70	NULL
and	NULL
pZVB10	NULL
,	NULL
failed	NULL
to	NULL
transactivate	NULL
the	NULL
mutated	NULL
NFkB	NULL
promoter	NULL
,	NULL
but	NULL
pZVH14	NULL
showed	NULL
slight	NULL
transactivation	NULL
(	NULL
8-	NULL
to	NULL
10-fold	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
confirmed	NULL
the	NULL
results	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
transactivating	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
included	NULL
within	NULL
the	NULL
pZVH14	NULL
clone	NULL
may	NULL
not	NULL
totally	NULL
depend	NULL
on	NULL
an	NULL
intact	NULL
NFkB	NULL
site	NULL
but	NULL
may	NULL
also	NULL
use	NULL
other	NULL
target	NULL
DNA	NULL
region	NULL
(	NULL
s	NULL
)	NULL
in	NULL
the	NULL
promoter	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
studies	NULL
demonstrate	NULL
that	NULL
two	NULL
strains	NULL
of	NULL
HHV-6	NULL
,	NULL
GS	NULL
and	NULL
Z29	NULL
,	NULL
can	NULL
infect	NULL
and	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
primary	NULL
,	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

However	NULL
,	NULL
these	NULL
two	NULL
strains	NULL
of	NULL
HHV-6	NULL
showed	NULL
distinct	NULL
differences	NULL
in	NULL
ability	NULL
to	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
related	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
two	NULL
strains	NULL
to	NULL
productively	NULL
infect	NULL
resting	NULL
T	NULL
lymphocytes	NULL
.	NULL

HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infected	NULL
both	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
infected	NULL
only	NULL
stimulated	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
observation	NULL
confirms	NULL
the	NULL
results	NULL
of	NULL
Wyatt	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41	NULL
)	NULL
,	NULL
who	NULL
showed	NULL
that	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
failed	NULL
to	NULL
replicate	NULL
in	NULL
nonacti-vated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
was	NULL
unable	NULL
to	NULL
infect	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
no	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
observed	NULL
.	NULL

However	NULL
,	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
even	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
active	NULL
replication	NULL
of	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
and	NULL
subsequent	NULL
production	NULL
of	NULL
its	NULL
gene	NULL
products	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
J.	NULL
Viror	NULL
.	NULL

HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
requires	NULL
essential	NULL
cellular	NULL
elements	NULL
that	NULL
are	NULL
provided	NULL
by	NULL
antigenic	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
for	NULL
its	NULL
replication	NULL
,	NULL
and	NULL
thus	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
by	NULL
Z29	NULL
may	NULL
require	NULL
cellular	NULL
cooperation	NULL
.	NULL

Ensoli	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
of	NULL
HIV-infected	NULL
T	NULL
cells	NULL
increases	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
HIV	NULL
mRNA	NULL
that	NULL
parallels	NULL
CAT	NULL
enzymatic	NULL
activity	NULL
.	NULL

It	NULL
is	NULL
quite	NULL
possible	NULL
that	NULL
similar	NULL
mechanisms	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
increase	NULL
in	NULL
CAT	NULL
enzymatic	NULL
activity	NULL
observed	NULL
here	NULL
.	NULL

Studies	NULL
are	NULL
currently	NULL
under	NULL
way	NULL
to	NULL
examine	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
by	NULL
the	NULL
cloned	NULL
gene	NULL
fragments	NULL
.	NULL

Certain	NULL
difficulties	NULL
are	NULL
inherent	NULL
in	NULL
these	NULL
types	NULL
of	NULL
experi-ments	NULL
.	NULL

We	NULL
have	NULL
observed	NULL
differences	NULL
in	NULL
HIV	NULL
promoter	NULL
activation	NULL
between	NULL
different	NULL
donors	NULL
and	NULL
even	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
when	NULL
cells	NULL
were	NULL
donated	NULL
at	NULL
different	NULL
times	NULL
(	NULL
6	NULL
months	NULL
later	NULL
)	NULL
.	NULL

Without	NULL
HHV	NULL
infection	NULL
or	NULL
antigenic	NULL
stimulation	NULL
,	NULL
the	NULL
background	NULL
CAT	NULL
activity	NULL
ranged	NULL
between	NULL
0.01	NULL
and	NULL
0.38	NULL
total	NULL
U	NULL
of	NULL
enzyme	NULL
activity	NULL
.	NULL

Because	NULL
the	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
is	NULL
based	NULL
on	NULL
the	NULL
background	NULL
activity	NULL
between	NULL
donors	NULL
or	NULL
experiments	NULL
,	NULL
this	NULL
parameter	NULL
can	NULL
not	NULL
be	NULL
used	NULL
to	NULL
compare	NULL
promoter	NULL
activity	NULL
but	NULL
must	NULL
be	NULL
used	NULL
to	NULL
measure	NULL
transactivation	NULL
within	NULL
a	NULL
single	NULL
experiment	NULL
.	NULL

This	NULL
was	NULL
not	NULL
expected	NULL
,	NULL
since	NULL
these	NULL
experiments	NULL
require	NULL
many	NULL
steps	NULL
of	NULL
long	NULL
incubation	NULL
periods	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
large	NULL
number	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
needed	NULL
for	NULL
each	NULL
experiment	NULL
(	NULL
>	NULL
100	NULL
x	NULL
10°	NULL
)	NULL
,	NULL
donors	NULL
were	NULL
only	NULL
bled	NULL
every	NULL
6	NULL
weeks	NULL
.	NULL

However	NULL
,	NULL
each	NULL
transfection	NULL
was	NULL
done	NULL
at	NULL
least	NULL
twice	NULL
on	NULL
two	NULL
different	NULL
healthy	NULL
adult	NULL
human	NULL
donors	NULL
.	NULL

Therefore	NULL
,	NULL
when	NULL
transactivation	NULL
was	NULL
observed	NULL
consistently	NULL
in	NULL
all	NULL
experiments	NULL
,	NULL
we	NULL
concluded	NULL
that	NULL
there	NULL
was	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
these	NULL
situations	NULL
.	NULL

A	NULL
number	NULL
of	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
identify	NULL
the	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
required	NULL
for	NULL
transactivation	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

In	NULL
earlier	NULL
studies	NULL
,	NULL
several	NULL
deletions	NULL
or	NULL
mutations	NULL
in	NULL
the	NULL
HIV	NULL
promoter	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
which	NULL
promoter	NULL
regions	NULL
were	NULL
essential	NULL
for	NULL
control	NULL
of	NULL
the	NULL
promoter	NULL
activity	NULL
during	NULL
primary	NULL
in	NULL
vitro	NULL
T-cell	NULL
stimulation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
altered	NULL
promoters	NULL
were	NULL
also	NULL
used	NULL
in	NULL
this	NULL
study	NULL
,	NULL
and	NULL
the	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
NFkB	NULL
region	NULL
was	NULL
essential	NULL
for	NULL
transactivation	NULL
during	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
HIV	NULL
promoter	NULL
containing	NULL
mutated	NULL
sequences	NULL
within	NULL
the	NULL
NFB	NULL
region	NULL
was	NULL
no	NULL
longer	NULL
activated	NULL
by	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
infection	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
directly	NULL
activates	NULL
the	NULL
NFB	NULL
cellular	NULL
protein	NULL
or	NULL
,	NULL
alternatively	NULL
,	NULL
a	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
gene	NULL
product	NULL
(	NULL
s	NULL
)	NULL
binds	NULL
directly	NULL
to	NULL
the	NULL
NFB	NULL
region	NULL
.	NULL

However	NULL
,	NULL
these	NULL
results	NULL
to	NULL
indicate	NULL
that	NULL
this	NULL
particular	NULL
promoter	NULL
region	NULL
seems	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
transactivation	NULL
during	NULL
an	NULL
active	NULL
infection	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
when	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
was	NULL
transfected	NULL
with	NULL
the	NULL
mutated	NULL
NFB	NULL
promoter	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
.	NULL

HHV-6	NULL
(	NULL
GS	NULL
)	NULL
is	NULL
not	NULL
unique	NULL
in	NULL
using	NULL
the	NULL
NFxB	NULL
site	NULL
,	NULL
since	NULL
it	NULL
has	NULL
been	NULL
noted	NULL
that	NULL
other	NULL
herpesviruses	NULL
,	NULL
such	NULL
as	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
cytomegalovirus	NULL
,	NULL
and	NULL
Epstein-Barr	NULL
virus	NULL
,	NULL
also	NULL
act	NULL
on	NULL
the	NULL
NFB	NULL
region	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
genome	NULL
of	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
has	NULL
been	NULL
estimated	NULL
to	NULL
be	NULL
about	NULL
170	NULL
kb	NULL
in	NULL
length	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
which	NULL
should	NULL
code	NULL
for	NULL
more	NULL
than	NULL
70	NULL
proteins	NULL
.	NULL

A	NULL
number	NULL
of	NULL
DNA	NULL
cloned	NULL
fragments	NULL
from	NULL
the	NULL
GS	NULL
genome	NULL
were	NULL
examined	NULL
in	NULL
this	NULL
study	NULL
to	NULL
determine	NULL
whether	NULL
they	NULL
code	NULL
for	NULL
products	NULL
that	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

Several	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
clones	NULL
,	NULL
comprising	NULL
about	NULL
40	NULL
%	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
,	NULL
were	NULL
individually	NULL
cotransfected	NULL
with	NULL
HIV	NULL
CAT	NULL
into	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Three	NULL
different	NULL
non-cross-hybridizing	NULL
DNA	NULL
clones	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
and	NULL
at	NULL
present	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
other	NULL
HHV-6	NULL
DNA	NULL
fragments	NULL
are	NULL
also	NULL
able	NULL
to	NULL
transactivate	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

The	NULL
DNA	NULL
clone	NULL
showing	NULL
the	NULL
highest	NULL
level	NULL
of	NULL
transactivation	NULL
(	NULL
pZVB70	NULL
)	NULL
contained	NULL
21.4	NULL
Vor	NULL
.	NULL

65	NULL
,	NULL
1991	NULL
kb	NULL
of	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
DNA	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
more	NULL
than	NULL
one	NULL
gene	NULL
product	NULL
expressed	NULL
from	NULL
this	NULL
plasmid	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
high	NULL
level	NULL
of	NULL
transactivating	NULL
ability	NULL
of	NULL
this	NULL
plasmid	NULL
.	NULL

Since	NULL
these	NULL
fragments	NULL
were	NULL
not	NULL
inserted	NULL
into	NULL
a	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
,	NULL
their	NULL
expression	NULL
requires	NULL
endogenous	NULL
promoter	NULL
activity	NULL
.	NULL

It	NULL
can	NULL
thus	NULL
be	NULL
inferred	NULL
from	NULL
these	NULL
data	NULL
that	NULL
at	NULL
least	NULL
some	NULL
of	NULL
the	NULL
HHV-6	NULL
promoters	NULL
must	NULL
be	NULL
active	NULL
in	NULL
both	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Two	NULL
other	NULL
plasmids	NULL
containing	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
fragments	NULL
also	NULL
transactivated	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
pZVH14	NULL
,	NULL
which	NULL
contained	NULL
an	NULL
8.7-kb	NULL
viral	NULL
fragment	NULL
,	NULL
and	NULL
pZVB10	NULL
,	NULL
which	NULL
contained	NULL
a	NULL
6.2-kb	NULL
fragment	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
open	NULL
reading	NULL
frames	NULL
present	NULL
in	NULL
these	NULL
fragments	NULL
,	NULL
the	NULL
DNA	NULL
was	NULL
sequenced	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

From	NULL
this	NULL
information	NULL
,	NULL
several	NULL
genes	NULL
have	NULL
been	NULL
identified	NULL
and	NULL
are	NULL
currently	NULL
been	NULL
subcloned	NULL
and	NULL
tested	NULL
for	NULL
transactivating	NULL
ability	NULL
on	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
pZVH14	NULL
clone	NULL
was	NULL
less	NULL
active	NULL
than	NULL
pZVB70	NULL
,	NULL
it	NULL
transactivated	NULL
HIV	NULL
CAT	NULL
in	NULL
the	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
and	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Of	NULL
interest	NULL
was	NULL
the	NULL
observation	NULL
that	NULL
this	NULL
fragment	NULL
,	NULL
pZVH14	NULL
,	NULL
was	NULL
unique	NULL
in	NULL
transactivating	NULL
the	NULL
mutant	NULL
NFB	NULL
promoter	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigenic	NULL
stimulation	NULL
.	NULL

No	NULL
such	NULL
activity	NULL
was	NULL
seen	NULL
after	NULL
GS	NULL
infection	NULL
of	NULL
T	NULL
cells	NULL
or	NULL
transfection	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
two	NULL
transactivating	NULL
DNA	NULL
fragments	NULL
from	NULL
GS	NULL
,	NULL
pZVB70	NULL
and	NULL
pZVB10	NULL
.	NULL

These	NULL
data	NULL
also	NULL
suggest	NULL
that	NULL
the	NULL
gene	NULL
products	NULL
expressed	NULL
from	NULL
pZVH14	NULL
are	NULL
able	NULL
to	NULL
act	NULL
on	NULL
regions	NULL
other	NULL
than	NULL
the	NULL
NFxB	NULL
site	NULL
,	NULL
independent	NULL
of	NULL
antigenic	NULL
stimulation	NULL
.	NULL

This	NULL
also	NULL
implies	NULL
that	NULL
gene	NULL
expression	NULL
from	NULL
this	NULL
DNA	NULL
fragment	NULL
is	NULL
possible	NULL
even	NULL
without	NULL
overt	NULL
cellular	NULL
stimulation	NULL
.	NULL

Since	NULL
transactivation	NULL
of	NULL
the	NULL
mutant	NULL
NFB	NULL
was	NULL
not	NULL
observed	NULL
during	NULL
an	NULL
actual	NULL
infection	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
,	NULL
the	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
contained	NULL
within	NULL
the	NULL
pZVH14	NULL
DNA	NULL
fragment	NULL
must	NULL
be	NULL
under	NULL
some	NULL
type	NULL
of	NULL
regulatory	NULL
control	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
has	NULL
shown	NULL
that	NULL
the	NULL
pZVH14	NULL
genomic	NULL
fragment	NULL
also	NULL
has	NULL
oncogenic	NULL
properties	NULL
(	NULL
32	NULL
)	NULL
.	NULL

At	NULL
present	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
the	NULL
gene	NULL
product	NULL
(	NULL
s	NULL
)	NULL
the	NULL
induce	NULL
transformation	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
is	NULL
the	NULL
same	NULL
product	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
.	NULL

The	NULL
immunodeficiency	NULL
disease	NULL
AIDS	NULL
is	NULL
a	NULL
chronic	NULL
disease	NULL
caused	NULL
by	NULL
the	NULL
human	NULL
retrovirus	NULL
HIV	NULL
.	NULL

The	NULL
time	NULL
from	NULL
HIV	NULL
infection	NULL
to	NULL
the	NULL
clinical	NULL
manifestation	NULL
of	NULL
AIDS	NULL
can	NULL
range	NULL
from	NULL
2	NULL
months	NULL
to	NULL
more	NULL
than	NULL
a	NULL
decade	NULL
(	NULL
2	NULL
,	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

An	NULL
important	NULL
determinant	NULL
of	NULL
the	NULL
length	NULL
of	NULL
this	NULL
latency	NULL
period	NULL
is	NULL
the	NULL
rate	NULL
of	NULL
HIV	NULL
replication	NULL
.	NULL

Factors	NULL
that	NULL
accelerate	NULL
HIV	NULL
replication	NULL
increase	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

After	NULL
HIV	NULL
infection	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
the	NULL
virus	NULL
undergoes	NULL
a	NULL
form	NULL
of	NULL
latency	NULL
until	NULL
activated	NULL
by	NULL
mitogens	NULL
or	NULL
specific	NULL
antigens	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
increases	NULL
HIV	NULL
promoter	NULL
activity	NULL
(	NULL
13	NULL
,	NULL
40	NULL
)	NULL
,	NULL
which	NULL
can	NULL
terminate	NULL
HIV	NULL
latency	NULL
.	NULL

Thus	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
promoter	NULL
can	NULL
be	NULL
a	NULL
factor	NULL
in	NULL
the	NULL
length	NULL
of	NULL
the	NULL
latency	NULL
period	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
,	NULL
other	NULL
DNA	NULL
viruses	NULL
,	NULL
such	NULL
as	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
cytomegalovirus	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
22	NULL
)	NULL
,	NULL
papovaviruses	NULL
(	NULL
11	NULL
)	NULL
,	NULL
adenoviruses	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
hepatitis	NULL
B	NULL
virus	NULL
(	NULL
36	NULL
)	NULL
,	NULL
have	NULL
been	NULL
implicated	NULL
as	NULL
possible	NULL
cofactors	NULL
in	NULL
AIDS	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
herpesvirus	NULL
cytomegalovirus	NULL
enhances	NULL
the	NULL
replication	NULL
of	NULL
HIV	NULL
in	NULL
coinfected	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
,	NULL
and	NULL
cells	NULL
productively	NULL
infected	NULL
with	NULL
both	NULL
CMV	NULL
and	NULL
HIV	NULL
have	NULL
been	NULL
found	NULL
in	NULL
the	NULL
brains	NULL
of	NULL
AIDS	NULL
patients	NULL
(	NULL
29	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
it	NULL
is	NULL
possible	NULL
for	NULL
DNA	NULL
viruses	NULL
,	NULL
especially	NULL
herpesviruses	NULL
,	NULL
to	NULL
activate	NULL
HIV	NULL
even	NULL
in	NULL
vivo	NULL
.	NULL

HHV-6	NULL
infects	NULL
primarily	NULL
CD4+	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
same	NULL
cells	NULL
infected	NULL
with	NULL
HIV	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
shown	NULL
that	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
can	NULL
be	NULL
productively	NULL
coinfected	NULL
with	NULL
HHV-6	NULL
and	NULL
HIV	NULL
(	NULL
6	NULL
,	NULL
24	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
many	NULL
of	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
HIV	NULL
LTR	NULL
BY	NULL
HHV-6	NULL
2901	NULL
the	NULL
initial	NULL
HHV-6	NULL
strains	NULL
were	NULL
isolated	NULL
from	NULL
individuals	NULL
suffering	NULL
from	NULL
AIDS	NULL
(	NULL
25	NULL
,	NULL
35	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
coinfection	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
with	NULL
HHV-6	NULL
and	NULL
HIV	NULL
could	NULL
accelerate	NULL
the	NULL
immunodeficiency	NULL
disease	NULL
caused	NULL
by	NULL
HIV	NULL
.	NULL

Ensoli	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
showed	NULL
that	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
could	NULL
be	NULL
productively	NULL
coinfected	NULL
with	NULL
HHV-6	NULL
and	NULL
HIV	NULL
,	NULL
resulting	NULL
in	NULL
accelerated	NULL
cell	NULL
death	NULL
and	NULL
increased	NULL
HIV	NULL
transcription	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
HIV	NULL
promoter	NULL
was	NULL
activated	NULL
in	NULL
HHV-6-infected	NULL
,	NULL
primary	NULL
human	NULL
T	NULL
lymphoblasts	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
recent	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
coinfection	NULL
of	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
with	NULL
HHV-6	NULL
and	NULL
HIV	NULL
suppressed	NULL
HIV	NULL
replication	NULL
(	NULL
6	NULL
,	NULL
24	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
these	NULL
studies	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
cells	NULL
that	NULL
were	NULL
infected	NULL
,	NULL
dosage	NULL
of	NULL
virus	NULL
,	NULL
and	NULL
time	NULL
of	NULL
infection	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
85	NULL
to	NULL
89	NULL
%	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
human	NULL
T	NULL
lymphoblasts	NULL
,	NULL
whereas	NULL
the	NULL
other	NULL
studies	NULL
(	NULL
6	NULL
,	NULL
24	NULL
)	NULL
used	NULL
stimulated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
which	NULL
contained	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
HHV-6	NULL
infects	NULL
numerous	NULL
cell	NULL
types	NULL
present	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
,	NULL
including	NULL
monocytes	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
25	NULL
,	NULL
26	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
mechanism	NULL
of	NULL
HIV	NULL
inhibition	NULL
by	NULL
HHV-6	NULL
in	NULL
these	NULL
studies	NULL
is	NULL
not	NULL
known	NULL
,	NULL
it	NULL
still	NULL
remains	NULL
possible	NULL
that	NULL
HHV-6	NULL
infection	NULL
of	NULL
cell	NULL
types	NULL
other	NULL
than	NULL
T	NULL
cells	NULL
contributes	NULL
to	NULL
suppression	NULL
of	NULL
HIV	NULL
replication	NULL
through	NULL
cytokine	NULL
production	NULL
.	NULL

This	NULL
study	NULL
has	NULL
demonstrated	NULL
that	NULL
HHV-6	NULL
gene	NULL
products	NULL
can	NULL
activate	NULL
the	NULL
HIV	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphoblasts	NULL
.	NULL

Therefore	NULL
,	NULL
an	NULL
active	NULL
HHV-6	NULL
infection	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
can	NULL
activate	NULL
an	NULL
otherwise	NULL
quiescent	NULL
HIV	NULL
promoter	NULL
.	NULL

This	NULL
promoter	NULL
activation	NULL
can	NULL
lead	NULL
to	NULL
an	NULL
increased	NULL
HIV	NULL
replication	NULL
and	NULL
consequently	NULL
enhances	NULL
T-cell	NULL
death	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
replication	NULL
of	NULL
HHV-6	NULL
itself	NULL
is	NULL
cytopathic	NULL
for	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
would	NULL
start	NULL
a	NULL
cycle	NULL
of	NULL
increased	NULL
T-cell	NULL
death	NULL
.	NULL

By	NULL
this	NULL
proposed	NULL
mechanism	NULL
,	NULL
an	NULL
active	NULL
HHV-6	NULL
infection	NULL
would	NULL
accelerate	NULL
the	NULL
progression	NULL
of	NULL
AIDS	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
study	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
American	NULL
Cancer	NULL
Society	NULL
postdoctoral	NULL
fellowship	NULL
grant	NULL
PF	NULL
03067	NULL
to	NULL
R.T.H	NULL
.	NULL

Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI	NULL
24115	NULL
and	NULL
AI30355	NULL
and	NULL
Wesley	NULL
Foundation	NULL
grant	NULL
9001008	NULL
to	NULL
C.W	NULL
.	NULL

,	NULL
and	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI	NULL
24224	NULL
,	NULL
A130355	NULL
,	NULL
and	NULL
BRSG-507-RRO573	NULL
to	NULL
N.B	NULL
.	NULL

We	NULL
thank	NULL
Michael	NULL
J.	NULL
Parmely	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
for	NULL
the	NULL
generous	NULL
use	NULL
of	NULL
his	NULL
laboratory	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
R.	NULL
C.	NULL
Gallo	NULL
for	NULL
providing	NULL
the	NULL
HHV-6	NULL
prototype	NULL
strain	NULL
GS	NULL
and	NULL
P.	NULL
Pellett	NULL
for	NULL
providing	NULL
the	NULL
HHV-6	NULL
(	NULL
Z29	NULL
)	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

1989	NULL
.	NULL

Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
.	NULL

2	NULL
.	NULL

Bacchetti	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
A.	NULL
R.	NULL
Moss	NULL
.	NULL

1989	NULL
.	NULL

Incubation	NULL
period	NULL
of	NULL
AIDS	NULL
in	NULL
San	NULL
Francisco	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
338:251-253	NULL
.	NULL

3	NULL
.	NULL

Balachandran	NULL
,	NULL
N.	NULL
,	NULL
R.	NULL
E.	NULL
Amelse	NULL
,	NULL
W.	NULL
W.	NULL
Zhou	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Chang	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
proteins	NULL
specific	NULL
for	NULL
human	NULL
herpesvirus	NULL
6-infected	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:2835-2840	NULL
.	NULL

4	NULL
.	NULL

Barre-Sinoussi	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
C.	NULL
Chermann	NULL
,	NULL
F.	NULL
Rey	NULL
,	NULL
M.	NULL
T.	NULL
Nugeyre	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
J.	NULL
Gruest	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
C.	NULL
Axler-Blin	NULL
,	NULL
F.	NULL
Vezinet-Brun	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
W.	NULL
Rozenbaum	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1983	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
T	NULL
lymphotropic	NULL
retrovirus	NULL
from	NULL
a	NULL
patient	NULL
at	NULL
risk	NULL
for	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
.	NULL

Science	NULL
220	NULL
:	NULL
868-871	NULL
.	NULL

5	NULL
.	NULL

Black	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
K.	NULL
C.	NULL
Sanderlin	NULL
,	NULL
C.	NULL
S.	NULL
Goldsmith	NULL
,	NULL
H.	NULL
E.	NULL
Gary	NULL
,	NULL
C.	NULL
Lopez	NULL
,	NULL
and	NULL
P.	NULL
Pellet	NULL
.	NULL

1989	NULL
.	NULL

Growth	NULL
properties	NULL
of	NULL
human	NULL
herpesvirus-6	NULL
strain	NULL
229	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

Methods	NULL
26:133-146	NULL
.	NULL

6	NULL
.	NULL

Carrigan	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
K.	NULL
K.	NULL
Knox	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Tapper	NULL
.	NULL

1990	NULL
.	NULL

Suppression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
by	NULL
2902	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

HORVAT	NULL
ET	NULL
AL	NULL
.	NULL

human	NULL
herpesvirus-6	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

162:844-851.	NULL
.	NULL

Castro	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
C.	NULL
D.	NULL
Weiss	NULL
,	NULL
L.	NULL
D.	NULL
Wiviott	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Levy	NULL
.	NULL

1988	NULL
.	NULL

Optimal	NULL
conditions	NULL
for	NULL
recovery	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

26:2371-2376.	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Lusso	NULL
,	NULL
F.	NULL
Schachter	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
F.	NULL
Negro	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
herpesvirus-6	NULL
increases	NULL
HIV-1	NULL
expression	NULL
in	NULL
co-infected	NULL
T	NULL
cells	NULL
via	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:3019-3027.	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
1988	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
:	NULL
infectiv-	NULL
ity	NULL
and	NULL
mechanisms	NULL
of	NULL
pathogenesis	NULL
.	NULL

Science	NULL
239:617-622	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
G.	NULL
M.	NULL
Shearer	NULL
,	NULL
M.	NULL
Kaplan	NULL
,	NULL
B.	NULL
F.	NULL
Haynes	NULL
,	NULL
T.	NULL
J.	NULL
Palker	NULL
,	NULL
R.	NULL
Redfield	NULL
,	NULL
J.	NULL
Oleske	NULL
,	NULL
B.	NULL
Safai	NULL
,	NULL
G.	NULL
White	NULL
,	NULL
P.	NULL
Foster	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Markham	NULL
.	NULL

1984	NULL
.	NULL

Frequent	NULL
detection	NULL
and	NULL
isolation	NULL
of	NULL
cytopathic	NULL
retroviruses	NULL
(	NULL
HTLV-II	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
at	NULL
risk	NULL
for	NULL
AIDS	NULL
.	NULL

Science	NULL
224:500-503	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
W.	NULL
Phelps	NULL
,	NULL
L.	NULL
Feigenbaum	NULL
,	NULL
J.	NULL
M.	NULL
Ostrove	NULL
,	NULL
A.	NULL
Adachi	NULL
,	NULL
P.	NULL
M.	NULL
Howley	NULL
,	NULL
G.	NULL
Khoury	NULL
,	NULL
H.	NULL
S.	NULL
Ginsberg	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Trans-activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
sequence	NULL
by	NULL
DNA	NULL
viruses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:9759-9763	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
C.	NULL
Wood	NULL
.	NULL

1989	NULL
.	NULL

HIV	NULL
promoter	NULL
activity	NULL
in	NULL
primary	NULL
antigen-specific	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

132:2745-2751	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
C.	NULL
Wood	NULL
,	NULL
and	NULL
N.	NULL
Balachandran	NULL
.	NULL

1989	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
promoter	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:970-973	NULL
.	NULL

Imagawa	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
M.	NULL
H.	NULL
Lee	NULL
,	NULL
S.	NULL
M.	NULL
Wolinsky	NULL
,	NULL
K.	NULL
Sano	NULL
,	NULL
F.	NULL
Morales	NULL
,	NULL
S.	NULL
Kwok	NULL
,	NULL
J.	NULL
J.	NULL
Sninsky	NULL
,	NULL
P.	NULL
G.	NULL
Nishanian	NULL
,	NULL
J.	NULL
Giorgi	NULL
,	NULL
J.	NULL
L.	NULL
Fahey	NULL
,	NULL
J.	NULL
Dudley	NULL
,	NULL
B.	NULL
R.	NULL
Visscher	NULL
,	NULL
and	NULL
R.	NULL
Detels	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
I	NULL
infection	NULL
in	NULL
homosexual	NULL
men	NULL
who	NULL
remain	NULL
seronegative	NULL
for	NULL
prolonged	NULL
periods	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

320:1458-1462	NULL
.	NULL

Isaksson	NULL
,	NULL
B.	NULL
,	NULL
J.	NULL
Albert	NULL
,	NULL
F.	NULL
Chiodi	NULL
,	NULL
A.	NULL
Furucrona	NULL
,	NULL
A.	NULL
Krook	NULL
,	NULL
and	NULL
P.	NULL
Putkonen	NULL
.	NULL

1988	NULL
.	NULL

AIDS	NULL
two	NULL
months	NULL
after	NULL
primary	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

158:866-853	NULL
.	NULL

Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
B.	NULL
Kramarsky	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
Jr.	NULL
,	NULL
P.	NULL
Peliet	NULL
,	NULL
A.	NULL
Buchbinder	NULL
,	NULL
S.	NULL
Memon	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1988	NULL
.	NULL

Molecular	NULL
studies	NULL
of	NULL
HHV-6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

Methods	NULL
21:179-190	NULL
.	NULL

Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
F.	NULL
Schachter	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1986	NULL
.	NULL

Genomic	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
B-lymphotropic	NULL
virus	NULL
(	NULL
HBLV	NULL
)	NULL
.	NULL

Science	NULL
234:601-603	NULL
.	NULL

Kashanchi	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
C.	NULL
Wood	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
is	NULL
functional	NULL
and	NULL
can	NULL
be	NULL
transactivated	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2157-2161	NULL
.	NULL

Klatzmann	NULL
,	NULL
D.	NULL
,	NULL
F.	NULL
Barre-Sinoussi	NULL
,	NULL
M.	NULL
Nugeyre	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
E.	NULL
Vilmer	NULL
,	NULL
C.	NULL
Griscelli	NULL
,	NULL
F.	NULL
Brun-Vezinet	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
J.	NULL
C.	NULL
Gluck-man	NULL
,	NULL
J.	NULL
C.	NULL
Chermann	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1984	NULL
.	NULL

Selective	NULL
tropism	NULL
of	NULL
lymphadenopathy-associated	NULL
virus	NULL
(	NULL
LAV	NULL
)	NULL
for	NULL
helper	NULL
inducer	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
225:59-62	NULL
.	NULL

Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
W.	NULL
A.	NULL
O'Brien	NULL
,	NULL
J.	NULL
Q.	NULL
Zhao	NULL
,	NULL
D.	NULL
W.	NULL
Golder	NULL
,	NULL
J.	NULL
C.	NULL
Gasson	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1988	NULL
.	NULL

Cytokines	NULL
alter	NULL
production	NULL
of	NULL
HIV-1	NULL
from	NULL
primary	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

Science	NULL
241	NULL
:	NULL
1673-1675	NULL
.	NULL

Lawrence	NULL
,	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

Molecular	NULL
interactions	NULL
among	NULL
herpesviruses	NULL
and	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

162:338-346	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
viruses	NULL
and	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS	NULL
.	NULL

JAMA	NULL
261:2997-3006	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
Landay	NULL
,	NULL
and	NULL
E.	NULL
T.	NULL
Lennette	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
herpesvirus	NULL
6	NULL
inhibits	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
in	NULL
cell	NULL
culture	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

28:2362-2364	NULL
.	NULL

Lopez	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
Pellett	NULL
,	NULL
J.	NULL
Stewart	NULL
,	NULL
C.	NULL
Goldsmith	NULL
,	NULL
K.	NULL
Sanderlin	NULL
,	NULL
J	NULL
.	NULL

Black	NULL
,	NULL
D.	NULL
Warfield	NULL
,	NULL
and	NULL
P.	NULL
Feorino	NULL
.	NULL

1988	NULL
.	NULL

Characteristics	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

157:1271-1273	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
B.	NULL
Ensoli	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
E.	NULL
Tschachler	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1989	NULL
.	NULL

Productive	NULL
dual	NULL
infection	NULL
of	NULL
human	NULL
CD4+	NULL
T	NULL
lymphocytes	NULL
by	NULL
HIV-1	NULL
and	NULL
HHV-6	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
337:370-373	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Rice	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Alternative	NULL
mechanisms	NULL
for	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
239	NULL
;	NULL
1299-1302	NULL
.	NULL

Nelson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
C.	NULL
Reynolds-Kohler	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

A.	NULL
Oldstone	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Wiley	NULL
.	NULL

1988	NULL
.	NULL

HIV	NULL
and	NULL
HCMV	NULL
coinfect	NULL
brain	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Virology	NULL
165:286-290	NULL
.	NULL

Neuman	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
C.	NULL
A.	NULL
Morency	NULL
,	NULL
and	NULL
K.	NULL
O.	NULL
Russian	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
novel	NULL
rapid	NULL
assay	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
expression	NULL
.	NULL

Biotechniques	NULL
5:444-447	NULL
.	NULL

Popovic	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
G.	NULL
Sarngadharan	NULL
,	NULL
E.	NULL
Read	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1984	NULL
.	NULL

Detection	NULL
,	NULL
isolation	NULL
,	NULL
and	NULL
continuous	NULL
production	NULL
of	NULL
cytopathic	NULL
retroviruese	NULL
(	NULL
HTLV-III	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
pre-AIDS	NULL
.	NULL

Science	NULL
224:497-500	NULL
.	NULL

Razzaque	NULL
,	NULL
A	NULL
.	NULL

1990	NULL
.	NULL

Oncogenic	NULL
potential	NULL
of	NULL
human	NULL
herpesvirus-6	NULL
DNA	NULL
.	NULL

Oncogene	NULL
5:1365-1370	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Saga	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Yoshikawa	NULL
,	NULL
Y.	NULL
Asano	NULL
,	NULL
T.	NULL
Yazaki	NULL
,	NULL
and	NULL
S.	NULL
Hirata	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
herpesvirus-6	NULL
infections	NULL
(	NULL
exanthem	NULL
subitum	NULL
)	NULL
without	NULL
rash	NULL
.	NULL

Pediatrics	NULL
83:1003-1006	NULL
.	NULL

Salahuddin	NULL
,	NULL
S.	NULL
Z.	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
S.	NULL
Sturzenegger	NULL
,	NULL
M.	NULL
Kaplan	NULL
,	NULL
G.	NULL
Halligan	NULL
,	NULL
P.	NULL
Biberfeld	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
B.	NULL
Kramarsky	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1986	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
new	NULL
virus	NULL
,	NULL
HBLV	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disor-ders	NULL
.	NULL

Science	NULL
234:596-601	NULL
.	NULL

Seto	NULL
,	NULL
E.	NULL
,	NULL
T.	NULL
S.	NULL
B	NULL
.	NULL

Yen	NULL
,	NULL
B.	NULL
M.	NULL
Peterlin	NULL
,	NULL
and	NULL
J.-H.	NULL
Ou	NULL
.	NULL

1988	NULL
.	NULL

Trans-activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
by	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8286-8290	NULL
.	NULL

Skolnik	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
B.	NULL
R.	NULL
Kosloff	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1988	NULL
.	NULL

Bidirectional	NULL
interactions	NULL
between	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
cytomegalovirus	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

157:508-514	NULL
.	NULL

Takahasi	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Sonoda	NULL
,	NULL
K.	NULL
Kawakami	NULL
,	NULL
K.	NULL
Miyata	NULL
,	NULL
T.	NULL
Oki	NULL
,	NULL
T.	NULL
Nagata	NULL
,	NULL
T.	NULL
Okuno	NULL
,	NULL
and	NULL
K.	NULL
Yamanishi	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
herpesvirus	NULL
6	NULL
and	NULL
exanthem	NULL
subitum	NULL
.	NULL

Lancet	NULL
i:1463	NULL
.	NULL

Tedder	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
M.	NULL
Briggs	NULL
,	NULL
C.	NULL
H.	NULL
Cameron	NULL
,	NULL
R.	NULL
Honess	NULL
,	NULL
D.	NULL
Robertson	NULL
,	NULL
and	NULL
H.	NULL
Whittle	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
novel	NULL
lymphotropic	NULL
herpes-virus	NULL
.	NULL

Lancet	NULL
ii:390-392	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
responds	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:6845-6848	NULL
.	NULL

Wyatt	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
N.	NULL
Balachandran	NULL
,	NULL
and	NULL
N.	NULL
Frenkel	NULL
.	NULL

1990	NULL
.	NULL

Variations	NULL
in	NULL
the	NULL
replication	NULL
and	NULL
antigenic	NULL
properties	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
strains	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

162:852-857	NULL
.	NULL

Zagury	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Bernard	NULL
,	NULL
R.	NULL
Leonard	NULL
,	NULL
R.	NULL
Cheynier	NULL
,	NULL
M.	NULL
Feldman	NULL
,	NULL
P.	NULL
S	NULL
$	NULL
.	NULL

Sarin	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1986	NULL
.	NULL

Long-term	NULL
cultures	NULL
of	NULL
HTLV-III	NULL
infected	NULL
T	NULL
cells	NULL
:	NULL
a	NULL
model	NULL
of	NULL
cytopathology	NULL
of	NULL
T-cell	NULL
depletion	NULL
in	NULL
AIDS	NULL
.	NULL

Science	NULL
231:850-853	NULL
.	NULL

